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Antimicrobial resistance (AMR) has emerged as a global threat to both human and 
animal health. Use of antimicrobials in food animals has been postulated as one of the 
drivers for selection of antimicrobial resistance. Recognizing the problem, FDA 
implemented a feed directive starting January 2017, which stopped the use of antibiotic 
growth promoters and extralabel use of medically important antimicrobials in food 
animals. Evaluation of the effectiveness of policy changes such as this feed directive 
requires long term surveillance of the prevalence of AMR in bacterial isolates of animal 
origin. However, the current knowledge about AMR in bacteria present in food animals, 
including swine, is mostly derived from cross-sectional studies and the existing data from 
NARMS has limited power to evaluate trends at a national level. 
Another public health concern is that drugs belonging to certain antimicrobial 
families of importance for public health, such as those included in the cephalosporin and 
fluoroquinolone families and are often reserved for secondary line treatments in humans, 
are used routinely in animal production in certain parts of the world. This use may be 
selecting for resistance against such critical drugs, thus creating a health risk for the 
human population. An in-depth knowledge of the molecular mechanisms responsible for 
AMR can aid in estimating the potential of transmission and the molecular epidemiology 
of AMR in different bacterial and host populations.  
The objectives of this dissertation were to study prevalence and changes in 
phenotypic and genotypic AMR in swine bacteria of clinical origin collected between 




In chapter 2, a detailed systematic review on the global prevalence of resistance to 
critical antimicrobials in swine E. coli was conducted. For colistin, cephalosporins and 
quinolones, the levels of AMR prevalence were higher in lower-middle income countries 
as compared to upper income countries. The prevalence of carbapenem resistance was 
low in most of the countries. Overall, this chapter summarized global prevalence of AMR 
as well as discrepancies and lack of harmonization in studies worldwide. 
In chapter 3, the prevalence and changes in AMR in swine clinical E. coli isolates 
in USA from 2006-2016 was analyzed. The prevalence of resistance to antimicrobials 
remained constant or changed modestly, except for a drastic increase in enrofloxacin 
resistance. Multivariate network analysis and rarefaction analysis revealed an increase in 
the density of AMR networks and an increase in number of combinations of different 
AMRs (resistotypes), respectively. These results suggest a change in AMR network at 
individual and multiple AMRs. 
In chapter 4, the prevalence and changes in AMR to swine clinical Streptococcus 
suis, Pasteurella multocida, Actinobacillus suis and Haemophilus parasuis isolates in 
USA from 2006-2016 was analyzed. Where clinical breakpoints or epidemiological cut-
offs were available, the prevalence of AMR remained low (<10%) for S. suis and P. 
multocida. For H.parasuis and A. suis, the effect of using surrogate breakpoints from 
related bacteria from different publications on estimating prevalence and trends was 
evaluated. The agreement in prevalence estimates for different bacterial-antimicrobial 
combinations depending on the breakpoint selected varied widely. For bacteria-
antimicrobials with no available breakpoints, ordinal regression models indicated a 




antimicrobials for H. parasuis. These findings indicate changes in resistance to certain 
antimicrobials in swine bacterial pathogens of animal health importance.  
In chapter 5, the genetic determinants of extended spectrum cephalosporin and 
fluoroquinolone resistance were studied in selected swine clinical E. coli isolates. 
Plasmids carrying ESBL-encoding genes and plasmid mediated quinolone resistance 
genes were assembled and described. Additionally, genes such as mcr-9 and fosA7 were 
identified in swine E. coli isolates in USA for the first time. These genes were present on 
diverse E. coli ST types spread throughout Midwest USA, indicative of a change in 
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CHAPTER -1 Introduction 
 
In the last decades antibiotic resistance has emerged as an extremely important problem 
affecting veterinary and human medicine. Antibiotics have been the cornerstone of 
modern medicine against infectious diseases, but it has been speculated that the 
emergence of antibiotic resistance may lead us to a post-antibiotic era in which common 
infections and minor injuries would be deadly once again.1 Use of antibiotics in animal 
production systems has been implicated as one of the causes for the increased prevalence 
of resistant bacteria in both animals and humans, and thus, it is considered a major public 
health issue.2 In food production systems antibiotics can be not only used for therapeutic 
purposes but also for prophylaxis and as growth promoters.3 It has been estimated that 
roughly 70% of all antibiotics produced in the world are consumed in food animal 
production systems.4 Moreover, several studies worldwide have reported the existence of 
bacteria isolated from animal production systems that are resistant against critical drugs 
used in human medicine, such as cephalosporins and fluoroquinolones.5 
Taking note of the impact of antibiotic use in animal production systems on AMR 
emergence, the FDA has recently taken initiatives to phase out the use of medically 
important antibiotics as growth promoters in animal production in the US, effective from 
January 2017.6 Restriction on the use of growth promoters is expected to contribute to a 
decrease in the prevalence of antibiotic resistant bacteria, extensively drug resistant and 
pandrug resistant bacteria in food animals.7 However, to evaluate the success or failure of 
such policies information about the baseline antimicrobial resistance levels is critically 




Antimicrobial Resistance Monitoring System (NARMS), performed on a relatively small 
number of isolates of certain bacterial species, there is little information available 
regarding the current status of antimicrobial resistance in bacteria from food animals. In 
addition to the dedicated active surveillance systems, passive data available from 
diagnostic labs, such as Minnesota Veterinary Diagnostic Lab (MVDL), can be used to 
analyze patterns of antimicrobial resistance in food production systems.8 In fact, Mather 
et al (2016) have suggested that passive surveillance using diagnostic based data might be 
more effective in detecting rare and emerging resistant phenotypes.9  
Previous field and in-vitro studies have suggested that resistance against one 
antibiotic may select for other unrelated antibiotics.10 For example, a recently published 
study demonstrated a statistical association between use of tylosin and tulathromycin in 
co-selection and persistence of chloramphenicol at Irish pig farms.11 Moreover, with an 
increase in available computational strength and new statistical models, co-resistance can 
be analyzed in novel ways.12 Currently, NARMS analyzes data at individual AMR level 
only. 
At a genetic level, resistance to a particular antimicrobial might be conferred by different 
mechanisms e.g. chromosomal mutations, horizontal transfer via plasmid-medianted 
resistance genes, etc.13 Understanding the genetic mechanisms behind AMR is crucial as 
different mechanisms might exert different fitness costs on bacterial cells. Recently, it has 
been characterized that colistin resistance in swine bacterial isolates can be induced by a 
stable, transferable plasmid carrying the mcr-1 resistance gene, whereas previously 
colistin resistance was only associated with an unstable chromosomal mutation.14 




different fitness costs on host bacteria. For example, in one experimental in-vitro study, 
the presence of a PMQR gene qnrA1 was found to decrease fitness by 9-21 %, whereas 
the presence of qnrS1 led to an increase in bacterial fitness by 7-21 %.15 Hence, 
knowledge of the molecular mechanisms behind phenotypic resistance might aid in 
understanding the emergence of specific AMRs and, when coupled with in-vitro and/or 
in-vivo studies, predict the success or failure of available mitigation measures. 
The US swine industry has grown rapidly over the last two decades in terms of 
pig crop as well as pigs per breeding animal, among other parameters.16 Minnesota 
accounts for nearly 12 % of the national hog and pig inventory, ranking third after Iowa 
and North Carolina.16 However, due to changes in consumer perception about 
antimicrobial use in food animal production systems,17 antimicrobial use in animal 
production including swine is under scrutiny. Some authors even suggest different 
taxation systems for antimicrobial-fed and antimicrobial-free meats.18 Hence, there is a 
critical need to assess the levels of antimicrobial resistance and its association with 
antimicrobial use in the swine industry from both animal health, human health and 
economics perspectives. 
The fact that dissemination of AMR is not restricted to a particular country further 
complicates this critical threat. International travel,19 food trade20 and role of migratory 
wildlife21 have all been implicated in transmission of bacteria resistance to critical 
antimicrobials across international borders. Recognition of AMR as a global threat rather 
than a regional one has been one of the key reasons behind setting up the Global 
Antimicrobial Resistance Surveillance system (GLASS) by WHO.22 The aim of this 




bacteria combinations globally, and collect and update the current status of AMR. 
Currently, the focus of this program is surveillance of human pathogens. The current 
knowledge about global prevalence and trends in AMR to critical antimicrobials in 
bacteria fromfood animal species remains unknown. A report on the current global status 
of AMR in a particular food animal species (such as swine) will complement the 




The objectives of this dissertation were to: 
1. To systematically collect and appraise information on the global prevalence of 
phenotypic and genotypic resistance to certain critical antimicrobials in isolates of 
indicator bacteria (Escherichia coli) collected globally from various sources of 
swine origin 
2. To analyze the prevalence and changes in resistance to a panel of antimicrobials 
in a pathobiont of both human and animal health importance (Escherichia coli) 
collected from diseased pigs in USA 
3. To determine the prevalence and changes in resistance to a panel of antimicrobials 
in pathogens involved in respiratory disease complex and polysystemic infections 
in swine in USA (Streptococcus suis, Pasteurella multocida, Actinobacillus suis 
and Haemophilus parasuis) 
4. To ascertain the genomic basis of extended spectrum cephalosporin and 





CHAPTER-2 Global Prevalence of Extended Spectrum Cephalosporin, 
Carbapenem, Colistin and Quinolone Resistance in Escherichia coli of 





The threat posed by the emergence of antimicrobial resistance (AMR) worldwide has led 
to an increased focus on monitoring both antimicrobial use (AMU) and AMR in public 
health. Undoubtedly, a high percentage of antimicrobials produced worldwide are 
consumed by animals,23 representing a possible driver and source of AMR that could 
impact both animal and public health. Although the link between AMU and development 
of AMR in animal production has been well demonstrated,24,25 the full impact of AMU 
on public and animal health is still not fully understood. To advance understanding of the 
complex epidemiology of AMR, it is necessary to monitor AMR in both domestic 
animals and humans, and many national and regional AMR monitoring systems include 
an animal and/or animal-based food component.26–28 Antimicrobial usage is particularly 
common in more intensified animal production systems, such as poultry and swine.29 In 
these animal species antimicrobials have been used to promote growth, for prophylaxis, 
metaphylaxis and as therapeutic agents against a multitude of bacterial pathogens,3 some 
of which are foodborne zoonoses.  
 The levels of concern associated with antimicrobial-resistant bacteria is 
influenced by the medical importance of the respective antimicrobials. The World Health 
Organization (WHO) has classified certain antimicrobial classes as being critically 
important for human medicine. These include third and higher generation cephalosporins, 




Some antimicrobials belonging to these classes, are also used in veterinary medicine, 
even though using these antimicrobials in animals could potentially lead to cross-
selection of genetic determinants of resistance to related antimicrobials used in human 
medicine.31 
 Resistance to extended-spectrum cephalosporins is mediated by extended 
spectrum beta-lactamases (ESBLs), (commonly encoded by the blaTEM-, CMY-, SHV-, CTX-M- 
family of genes) and plasmidic AmpC (commonly encoded by the blaCMY family of 
genes).32 The epidemiology of AMR is complicated by the numerous genes that encode 
for resistance to antimicrobials in the same or different antimicrobial class. For example, 
ESBL genes (like blaVIM-, IMP-, OXA-48, NDM-) encode resistance determinants to various 
cephalosporins and carbapenems,33 and might show variable substrate specificity.34 
Moreover, some of these resistance mechanisms are either novel or have been discovered 
only recently. Recent discoveries of plasmid mediated genes encoding colistin resistance 
(mcr) are another example of the constantly evolving threat of AMR, reinforcing the need 
for genomic epidemiology in AMR surveillance.14 Similarly, resistance to nalidixic acid 
(NAL) and fluoroquinolones (FQs) was thought to be mediated by chromosomal 
mutations and increased activity of efflux pumps.35 However, in the last two decades 
plasmid-mediated mechanisms of quinolone resistance (PMQRs) have been increasingly 
reported, making the genomic basis of FQ- and NAL-resistance even more complex than 
initially considered.36 
 Escherichia coli is a commensal bacterium and potential pathogen found in the 
intestinal microflora of animals and humans. E. coli is favored as an indicator bacterium 




and propensity to acquire and disseminate resistance carrying plasmids.37 This bacterium 
is also easily isolated from water, environmental samples and raw animal-based products 
and hence has been used extensively as an indicator of AMR across the food chain. For 
example, presence of similar genetic determinants of AMR in E. coli isolated from 
humans and food animals have been considered evidence of transfer of AMR across the 
food chain.38 
 Because of the widespread interest in AMR among clinicians, veterinarians and 
public health practitioners, there has been an exponential increase in the number of 
scientific publications focusing on this topic, particularly in recent years. The objective of 
this systematic review was to describe geographical distribution and temporal changes in 
the prevalences of phenotypic and genotypic resistance to critically important 
antimicrobial classes (third and fourth generation cephalosporins, carbapenems, colistin, 
quinolones) in this widely used indicator bacterial species among isolates from swine, a 





Four databases (PubAg, Web of Science, Pubmed and CAB abstracts) were selected after 
consultation. The search strings employed have been provided in supplementary material 
(S2-1). All the databases were initially searched on April 13, 2017 and updated on July 
27, 2018. References were retrieved and imported to Mendeley (Mendeley Ltd., version 
1.17.13) and duplicate articles were removed. Additionally, reports on AMR in E. coli 
from swine and/or pork not indexed in scholarly databases were identified from the 




antimicrobial resistance (EFSA-European countries, DANMAP-Denmark, MARAN- The 
Netherlands, NORMVET-Norway, SVEDRES-Sweden, FINRES-Finland and CIPARS-
Canada). 
The relevance of the retrieved references (titles and abstracts when available) was 
first screened by three reviewers by determining if there was a mention to antimicrobial 
resistance, Escherichia coli or Enterobacteriaceae, and livestock in general. The full-
texts of citations retained at this stage were then retrieved and subjected to a second 
screening in which relevant data were extracted (see below). Data were collected from 
articles meeting the following three inclusion criteria: 
1. There was data on prevalence of genotypic and/or phenotypic antimicrobial resistance 
cephalosporins, FQ, NAL, colistin and/or polymyxin E   
2. Resistance was measured in Escherichia coli 
3. E. coli were retrieved from pigs and pork or meat products of porcine origin (hereon 
referred to as “PMP”) 
Studies were excluded if the articles were written in a language other than 
English; if they provided no original data (review articles); if they were experimental in 
nature (drug trials under experimental conditions, manipulation of plasmids etc.); if 
information was not provided for E. coli or bacteria were not isolated from pigs/PMP; if a 
denominator (number of isolates tested) from which the resistant isolates were obtained 
was not provided; if bacterial isolates were not clearly classified as resistant/non-resistant 
by the authors or information to classify them as such was not provided; or if the articles 




were reviewed and data were extracted at this stage by lead reviewer, except for data 
from articles published from 2000-2006 which were extracted by another reviewer. 
Data extraction 
 
Data from articles retained after the application of inclusion/exclusion criteria 
were compiled into a Microsoft Excel spreadsheet. Data extracted included year of study, 
first author’s last name, country in which the study was conducted, health status of the 
studied pig population, type of samples from which the bacteria were recovered, 
methodology used to assess bacterial antimicrobial susceptibility, antimicrobials tested, 
criteria for classifying bacteria as resistant/non-resistant, total number of isolates tested 
and number of isolates resistant to each antimicrobial. 
Statistical analysis 
 
In our literature search, prevalence of genetic mechanisms encoding for 
cephalosporin resistance was studied either in E. coli populations collected without any 
bias of antibiotic enrichment or phenotypic resistance (hereon referred to as “general-
EC”) or in ESBL-E. coli (ESBL-EC) populations. ESBL-EC were defined in the studies 
based on phenotypic methods suggested by CLSI or presence of genes conferring ESBL 
phenotype. Countries were classified as upper income countries (UIC) if these belong to 
high income class, or lower-middle income countries (LMIC) if these countries were in 
upper-middle income, lower-middle income or low-income classes, based on World Bank 
classification.39 Pooled prevalences of specific AMR (cefotaxime, ceftiofur, ceftazidime, 
colistin, fluoroquinolones and nalidixic acid) in general-EC and ESBL-EC prevalence 
were calculated at the country level, and separately for isolates collected from healthy 




genes in general-EC at a country level. Proportions of resistance to each antimicrobial 
were first transformed using Freeman-Tukey double arcsine transformation, and pooled 
estimates were then calculated using a random effects model using empirical Bayes 
estimator and back-transforming the estimates.40 Crude percentage prevalences were 
reported for bla and qnr genes in ESBL-EC and phenotypic carbapenem resistance in 
general-EC because of lack of sufficient number of articles and/or isolates. These 
country-level estimates were classified as very low (<1%), low (1.1-10%), moderate (10-
20%), high (20-50%), very high (50-70%) and extremely high (70-100%) as per EFSA 
guidelines.41 
To study changes in the prevalence of resistant general-EC and ESBL-EC over 
time, hierarchical multivariable generalized linear mixed models were fitted using 
restricted maximum-likelihood estimation (REML). In these models, raw percentage of 
resistance to individual antimicrobials (cefotaxime, colistin, ceftiofur, ceftazidime, FQ 
and NAL) in general-EC or ESBL-EC prevalence at the study level were considered as 
the outcome variables; time (in years), income levels of countries and source (healthy 
pigs and PMP vs diseased pigs) as fixed effects and country as hierarchical random effect. 
Data from pigs of unknown clinical status were pooled with the data from healthy pigs 
for meta-analysis. For the articles where data were collected over several years, the 
midpoint of the study period was used in the analyses. For example, if data were 
collected between 2008 and 2012 and information about individual years was not 
provided, then 2010 was considered as the time point in the analysis. Some articles did 
not provide data on the year of sample collection. For these articles, an estimated time-




with complete information on year of sample collection and year of publication. Meta-
analyses were performed using ‘metafor’ package in RStudio version 1.0.136 using 




Literature search  
 
The initial search conducted on the four databases retrieved 4,037 references. 
Additionally, data from 70 surveillance reports from national and international agencies 
were also included in the literature review. After removal of duplicate articles, the 
relevance of 2,869 references was assessed through the screening of their title and 
abstracts. Of these, 1,082 references were deemed relevant and their full texts retrieved 
and subjected to the second screening (Figure 2-1). Finally, data from a total of 324 
articles included in this literature review were extracted.  
Characteristics of articles included 
 
The characteristics of articles included in the final stage of the review (n=324) are 
presented in table 2-1. The studies included were published between 1983 and 2018, with 
nearly 62% of them being published after 2010. Articles contained data about isolates 
collected from as early as 1974 and as recently as 2018. Overall, data on resistance on E. 
coli recovered from pig or PMP from 55 countries was retrieved. Most of the articles 
selected reported data from European (158 articles, 48.8%) or Asian (101 articles, 31.2%) 
countries. All except two articles (n=322) contained data on isolates recovered from pig 
samples, and 62 articles included data on isolates on PMP. Among the studies of E. coli 




resistance data were available from 300 articles and were predominantly derived from 
dilution methods (agar dilution or broth microdilution) (n=173, 57.7%) and disk diffusion 
(n=124, 41.3%) methods. In the 266 articles containing data about cephalosporin 
resistance and published after 2000, 163 and 53 articles used the CLSI breakpoints or 
guidelines issued by EUCAST, respectively. Forty articles did not specify the interpretive 
criteria used to categorize isolates as susceptible/resistant. Since the interpretive criteria 
for colistin and carbapenem were introduced only in the last decade, many authors used 
manufacturer-based cut-offs or cut-offs suggested by other scientists. Hence, use of 
interpretive criteria was not evaluated for carbapenem and colistin resistance. 
Prevalence of phenotypic and genotypic antimicrobial resistance 
 
Very low to low (<10 %) prevalences of resistance to third generation cephalosporins 
(ceftazidime, ceftiofur and cefotaxime) were estimated for general-EC isolates collected 
from healthy pigs, diseased pigs and PMP in Europe, with the exception of ceftiofur 
resistance in isolates collected from diseased pigs in Spain (10.6%) and Romania⁠ 
(18.0 %) (figures 2-2, 2-3, 2-4, 2-5, 2-6; tables 2-2, 2-3, 2-4). 
 By comparison, the prevalences of resistance to ceftiofur were more heterogenous 
in general-EC isolates collected from Asia (figures 2-2, 2-3; table 2-2). While these 
prevalences were very low to low (<10 %) in isolates collected from healthy and diseased 
pigs from Japan ⁠, South Korea, Taiwan, Thailand and Vietnam, moderate to high 
prevalences of ceftiofur resistance were estimated in general-EC isolates collected from 




In North America and Australia, prevalences of ceftiofur resistance were very low 
to low (<10%) in general-EC isolates from all 3 sources collected from Australia, Canada 
and the United States of America (USA), except for moderate prevalences of ceftiofur 
resistance in general-EC isolates collected from PMP in USA (12.0%) (figures 2-2, 2-3; 
table 2-2). Low prevalences of ceftiofur resistance were estimated from general-EC 
isolates collected from healthy pigs in South America (Argentina ⁠-6.1%; Brazil⁠-2.6%). 
However, 14.9% of the general-EC isolates collected from diseased pigs in Argentina 
were resistant to ceftiofur (figure 2-3; table 2-2). 
Moderate to high prevalences (10-50%) of cefotaxime resistance were estimated 
for general-EC isolates collected from China (12.3%, healthy pigs; 18.8%, diseased pigs), 
India⁠ (28.7%, healthy pigs; 36.1%, diseased pigs), Thailand (32.7%, healthy pigs; 10.5% 
diseased pigs) and South Africa ⁠ (14.5%, healthy pigs) (figures 2-4, 2-5; table 2-3). In 
Nigeria, 73.7% of general-EC isolates collected from healthy pigs were ceftiofur resistant 
(figures 2-4, 2-5; table 2-3). ⁠Other non-European countries that had lower prevalences 
(<10%) of cefotaxime resistance in general-EC isolates collected from healthy and 
diseased pigs were Australia, Cambodia ⁠, Canada, Chile ⁠, Cuba, Grenada, Japan ⁠, South 
Korea⁠ and Taiwan (figures 2-4, 2-5; table 2-3). 
Among the general-EC isolates collected from healthy and diseased pig sources, 
prevalences of ceftazidime resistance were low (<10%) in some Asian countries 
(Cambodia, South Korea, Taiwan and Vietnam), Argentina ⁠, Australia and Grenada (figure 




collected from China ⁠ (2.26%, healthy pigs; 12.4%, diseased pigs), Thailand (18.5%, 
healthy pigs; 3.61%, diseased pigs) and Nigeria (74.5%, healthy pigs) (figure 2-6; table 2-
4). An extremely high prevalence of ceftazidime resistance was observed in general-EC 
isolates collected from meat products in Egypt ⁠ (62.7%) and diseased pigs in India ⁠ 
(99.9%) (figure 2-6; table 2-4). 
Pooled prevalence of ESBL-EC was consistently very low to low (<10 %) in 
European countries ⁠, except for isolates from healthy pigs in Portugal (14.3%) (table 2-5). 
Again, a greater variability was observed in studies from Asian countries, in which 
prevalences of ESBL-EC were found to be very low to low (Japan ⁠ and South Korea), 
moderate to high (Cambodia ⁠, China⁠, India⁠, Vietnam and Taiwan) and very high to 
extremely high (Hong Kong and Thailand ⁠) depending on the country and the source 
(table 2-5). Higher prevalences of ESBL-EC (25.1-43.2%) were estimated in isolates 
from diseased pigs from China and India compared to isolates from healthy pigs (ranging 
between 18-20 %) (table 2-5), whereas the opposite was observed in Thailand, where 
ESBL-EC prevalences were higher for isolates from healthy pigs (48.9%) as compared to 
diseased pigs (12.0%) (table 2-5).  The prevalences of ESBL-EC in isolates from PMP 
were also very variable, ranging between low prevalence in Japan (2.79%) to higher 
prevalence in Vietnam (31.9%) (table 2-5). From the Americas and Africa, only estimates 
from Brazil and Nigeria ⁠ were available, where the prevalence of ESBL-EC resistance 




Pooled prevalences of blaSHV, blaCTX-M, blaCMY and blaTEM genes in general-EC 
populations were estimated (table 2-6). Overall prevalences of blaSHV and blaCTX-M genes 
were below 10% in all countries with data available (table 2-6). Pooled prevalences of 
blaCMY were similarly low in these populations with the exception of USA, where nearly 
38.4% of general-EC isolates carried blaCMY genes (table 2-6). Pooled prevalences of 
blaTEM were low (<10%) in isolates from Bulgaria ⁠, Canada and India⁠ (table 2-6). In 
contrast, pooled prevalences of blaTEM were moderate to high (14.4-49.6%) in general-
EC isolates collected in China ⁠, Czech Republic, Denmark, Poland and USA ⁠ (table 2-6). 
Notably, general-EC isolates from Australia (55%) ⁠ and Thailand (94.1%) had very high 
to extremely high prevalence of blaTEM genes (table 2-6). 
 Raw percentage prevalences of bla genes in ESBL-EC populations are presented 
in table 2-7. Briefly, the prevalences of blaSHV genes were nearly zero percent in 6 
countries from which data was available for more than 20 isolates (Canada ⁠, China, 
Germany, Taiwan ⁠, Thailand and Vietnam) (table 2-7). However, nearly 9%, 16%, 33% 
and 62% of United Kingdom (UK), Belgian, Spanish and South Korean ESBL-EC 
isolates carried these genes, respectively. The distribution of blaCMY genes among ESBL-
EC was highly variable, ranging from 1.89% to 96.5% across ESBL-EC isolates collected 
from different countries (table 2-7). Similarly, the distribution of blaTEM genes among 
ESBL-EC isolates was also extremely variable, ranging from 27.0% to nearly 100% 
among ESBL-EC isolates from Germany and South Korea ⁠, respectively (table 2-7). With 
the exception of 3rd generation cephalosporin resistant isolates from Canada, more than 




isolates carried blaCTX-M gene (table 2-7). More than 80% of ESBL-EC isolates from 
Belgium ⁠, Germany, Japan ⁠, The Netherlands, Taiwan ⁠, UK and Vietnam carried this group 
of genes (table 2-7).  
At least 21 different blaCTX-M alleles were reported across general and ESBL-EC 
populations across all studies (table 2-8). ESBL-EC isolates from China carry the most 
diverse repertoire of blaCTX-M alleles, with at least 14 different blaCTX-M alleles reported 
so far (table 2-8). Among the European countries, ESBL-EC isolates from UK carried 7 
different allele types, followed closely by Germany with 5 different allele types (table 2-
8). blaCTX-M-1 was the most widespread allele, with nearly 59% of ESBL-EC from 12 
countries carrying it (table 2-8). Other notable genes prevalent worldwide were blaCTX-M-9 
(32.5%), blaCTX-M-14 (16.6%), blaCTX-M-15 (12.4%), blaCTX-M-55 (18.5% in Asian isolates) 
and blaCTX-M-65 (12.1%) (Table 2-8).  
Overall prevalences of carbapenem resistance were found to be extremely low 
(0.48%, n=65/13,451 general-EC isolates collected from 39 countries, table 2-9). 
Carbapenem resistant general-EC isolates were reported from Australia (0.39%, 
n=2/519), China (1.37%, n=11/805), Germany (0.89%, n=4/450), Greece (3.59%, 
n=6/167)⁠, India (20.5%, n=23/112) ⁠, South Africa (1.78%, n=3/169) ⁠, South Korea 
(0.77 %, n=1/130), The Netherlands (0.14%, n=3/2159) ⁠, Portugal (0.37%, n=1/264) and 
Thailand ⁠ (0.38%, n=2/520) (table 2-9). Additionally, in a study focusing on general-EC 
isolates from European countries, 0.14% (11/7850) of isolates were carbapenem 
resistant.44 While none of the ESBL-EC isolates from healthy pigs in Germany 




percent of the ESBL-EC isolates collected from animals in Brazil (n=8/28) and South 
Korea (n=9/469) were phenotypically carbapenem resistant, respectively.45–52 None of the 
79 colistin resistant isolates from sick pigs tested in France were carbapenem resistant.53  
Additionally, genes coding for carbapenem resistance were also found in general-
EC isolated from healthy pigs in Germany (blaVIM-1, 2/238, blaOXA-48, blaNDM, 
blaKPC=0/238) ⁠and diseased pigs in China (blaIMP-1, 1/315).54–56 Genes encoding 
carbapenem resistance encoding genes were not found in a limited number of general-EC 
isolates isolated from different sources USA (n=199, genes tested= blaNDM-1)
 or Denmark 
(n=54, genes tested= blaVIM-2, blaIMP-2).
57,58 
 In South Korea, a large spectrum of genes encoding for carbapenem resistance 
were found in ESBL-EC isolates collected from healthy pigs (blaNDM-1-14.7%, blaKPC-
12.6%, blaVIM-5.3%, n= 95).
49 ⁠ In Germany, a single isolate out of 221 ESBL-EC isolates 
collected from healthy, fattening pigs was found to be harboring blaVIM-1 gene.
59 
Additionally, among carbapenem resistant isolates collected in China, all 5 and 9 isolates 
possessed blaNDM-1 and blaNDM-5, respectively in different studies.
60,61 Eight out of 23 
Indian and 2 out of 11 European carbapenem resistant isolates carried blaNDM-1 and 
blaOXA-181 genes, respectively.
44 
In Europe, prevalences of colistin resistance ranged between very low and low in 
general-EC isolates from all sources, except Spanish and Serbian isolates from diseased 
pigs, in which higher prevalences of resistance (23.4-33.8%) were found (figures 2-7, 2-




 In Asian countries, very low (<1%) and moderate-high (16.6-34.5%) prevalences 
of colistin resistance were reported among general-EC isolates from healthy and diseased 
pigs in ⁠ Japan and South Korea, respectively (figure 2-7, 208; table 2-10). Moderate to 
high prevalences of prevalence (11.7-31.2%) of colistin resistance were found in general-
EC isolates from both healthy and diseased pigs in Cambodia, ⁠ China, Thailand, and 
Vietnam (figure 2-7, 2-8; table 2-10). Prevalences of colistin resistance were very low 
and high in general-EC isolates collected from healthy pigs in Zambia (0.26%) ⁠ and 
diseased pigs in Brazil (23%), respectively (figure 2-7, 2-8; table 2-10).  
 Additionally, none of the ESBL-EC isolates from healthy pigs and tested for 
phenotypic resistance in Thailand (n=80) and UK (n=190) were colistin resistant.52,62 
However, 6.5% of the 214 ESBL-EC isolates from healthy pigs in Italy were colistin 
resistant.63 In ESBL-EC isolates from China, none of the 198 isolates from diseased pigs 
and 36.1% (n=35/97) of the isolates from healthy pigs were phenotypically tested to be 
colistin resistant.64,65 While our search revealed no general-EC or ESBL-EC isolates that 
were tested for colistin resistant in Taiwan, 45.9% (n=161/351) of the florfenicol resistant 
isolates were colistin resistant.66 
Globally, a total of 475 (2.66%) of the 17,838 general-EC isolates collected 
between 2015-2018 from different sources harbored mcr-1 (table 2-6). ⁠ The pooled 
prevalences of mcr-1 gene in general-EC population were very low (<1%) in 10 out of 15 
countries spread across three continents, low in 3 countries (Japan, ⁠ Spain and Venezuela⁠) 




Presence of mcr-2 was studied in 2,519 general-EC isolates collected from 
healthy and diseased pigs in China, Italy, Japan and Spain but none of the isolates carried 
this gene.62,63,67,68 Similarly, none of the 299 general-EC isolates from diseased pigs from 
China and Spain carried mcr-3.63,67,69 None of the 169 general-EC isolates collected from 
healthy pigs in Italy carried mcr-3, mcr-4 and mcr-5.63 However, 54.8% (102/186) and 
2.69% (5/186) general-EC isolated from diseased pigs in Spain had mcr-4 and mcr-5, 
respectively.69 
In ESBL-EC isolates tested from healthy pigs in UK (n=190) and Vietnam 
(n=39), none carried mcr-1.50,62 ⁠ In contrast, 31.2% (378/1213) isolates resistant to 3rd 
generation cephalosporins collected from healthy and diseased pigs in China also carried 
mcr-1.64,65,70 ⁠ In isolates collected from Germany which were either resistant to 
cefotaxime or enrofloxacin resistance, 10.6% (n=69/652) carried mcr-1.55,71 Although 
none of the 214 ESBL-EC isolates collected from pigs at slaughter in Italy carried mcr-2, 
mcr-3 or mcr-5, one of these isolates carried a mcr-4 gene and 13 isolates carried mcr-1 
gene.63 ⁠Additionally, 4 of the 9 carbapenem resistant isolates and 45 of the 101 
enrofloxacin resistant isolates collected from China carried mcr-1.61,72 Studies reporting 
prevalence of mcr-1 in phenotypically colistin resistant isolates revealed that while only 
13.2% of the Belgian isolates carried mcr-1, prevalences of this gene in colistin resistant 
isolates from China, France and Portugal were 96.3% (n=78/81), 88.6% (n=70/79) and 
100% (n=90/90), respectively.53,72–74 
Briefly, FQ-resistance was very low-low (<10%) in isolates from healthy animals 




Spain and Cyprus (high, between 29.3-43.7%) (Figure 2-9; table 2-11). Prevalences of 
NAL-resistance also ranged between very low- low (<10%) in European countries, 
except for moderate resistance (10.4-24.6%) for isolates collected from healthy animals 
in Croatia, Cyprus, Iceland, Romania and Spain (table 2-12). The prevalences of FQ- and 
NAL-resistance among PMP isolates recovered from Europe were also very low-low 
(<10%) except for isolates from Greece (FQ-resistance -15.8%) (tables 2-11 and 2-12).  
 The prevalences of FQ-resistance were higher in isolates cultured from diseased 
animals from European countries, with these prevalences ranging from low (Belgium, 
Czech Republic, Denmark, Norway, Sweden, United Kingdom) to moderate (Bulgaria, 
Finland, France, Switzerland, range-11.2 to 18.8%), high (Croatia, Estonia, Latvia, 
Lithuania, Portugal, Serbia and Spain, range-20.5 to 49.9%), and extremely high 
(Romania-78.3%) (figure 2-10; table 2-11). Similarly, except for isolates from Norway 
and United Kingdom, isolates from diseased animals in other European countries were 
moderately (Denmark-13.8%) to highly (Belgium, Croatia, Estonia, Finland, Latvia, 
Lithuania, Spain, Switzerland, range-20.8 to 47.2%) NAL-resistant (table 2-12). Notably, 
isolates from diseased animals in Portugal were extremely resistant to NAL (84.5%) 
(table 2-12). 
 For Asian countries, low prevalences of FQ- and NAL-resistance were rarely 
reported, with only isolates from healthy animals in Japan presenting low prevalences of 
resistance (0.96 -2.58%) (figure 2-9; tables 2-11 and 2-12). In isolates from healthy 
animals, prevalences of FQ- resistance ranged from moderate (South Korea-14.0%) to 
high (Cambodia, China, India, Thailand, Vietnam; range-24.3 to 47.3%) (figure 2-9; table 




countries, with prevalences ranging from high (Cambodia-20.6%; South Korea-36.9%) to 
extremely high (China, India, Thailand; range- 68.1 to 74.8%) (table 2-12).  
 Similarly, in Asian countries, isolates from diseased animals were consistently 
moderately to highly resistant against FQ and NAL (figure 2-10; tables 2-11 and 2-12). 
Except for isolates from India (9.40% FQ-resistance), isolates from Japan, Thailand and 
Vietnam were moderately FQ-resistant (10.4-15.4%) whereas isolates from South Korea 
(48.5%), China (67.2%) and Taiwan (85.2%) were high to extremely FQ-resistant (figure 
2-10; table 2-11). Isolates from diseased animals tested for NAL-resistance were either 
highly resistant (Japan, India- 34.5 to 39.3%) or extremely resistant (China, South Korea, 
Taiwan- 55.9 to 95.1%) (table 2-12).  
 From certain other countries (Australia, Canada, Grenada, New Zealand, Nigeria, 
Uganda, United States of America), prevalences of FQ- and NAL-resistance in isolates 
collected from various sources were very low to low (<10%) except for moderate NAL-
resistance in isolates from diseased pigs in Nigeria (15.5%) and high NAL-resistance in 
PMP isolates from United States of America (23.9%) (figures 2-19, 2-10; tables 2-11 and 
2-12). Although prevalences of FQ-resistance in isolates from healthy animals in Brazil 
and Chile were low, isolates from diseased animals were moderately NA-resistant (Chile-
11.8%) or highly FQ- and NAL-resistant (Brazil, 24.6-40.4%) (figures 2-9, 2-10; tables 
2-11 and 2-12). Prevalence of resistance in isolates from Argentina varied from 
moderately FQ-resistant (healthy animals-11.9%), highly NAL-resistant (healthy 
animals-32.6%) and very highly FQ-resistant (diseased animals-57.1%) (figures 2-9, 2-
10; tables 2-11 and 2-12). South African isolates from healthy animals were either 




and 2-12). Isolates collected from PMP in Egypt were highly FQ-resistant (47.5%) (table 
2-11).   
 Data on FQ- and NAL-resistance in extended spectrum beta-lactamase carrying 
E. coli (ESBL-EC, conferring resistance against 3rd and 4th generation cephalosporins) 
were available in 13 countries and are summarized in table 2-13. Except for Canada, 
where none of the 85 ESBL-EC isolates were ciprofloxacin resistant, percentage of 
ESBL-EC which were also ciprofloxacin resistant ranged from 12.8% (n=5/39) in 
Vietnam to 100% (n=54/54) in Taiwan (table 2-13). This phenomenon of co-resistance 
was also observed in ESBL-EC isolates collected from European countries such as Spain, 
Germany and Portugal. The percentages of ESBL-EC isolates resistant to NAL were even 
higher (table 2-13). 
Genotypic information was available for E. coli isolates collected between 1993 
and 2017 and described in 18 articles. None of the general-EC isolates recovered from 
healthy animals or PMP in Australia (n=72, healthy animals) and Czech Republic (n=27-
healthy animals, 32-PMP) carried qnrA, qnrB or qnrS genes.75–77 The percentage of qnrA 
in general-EC isolates from Asian countries ranged from zero (n=206 isolates-healthy 
animals, Thailand; 378 isolates- healthy animals, China) and 0.36% (n=6/1,679 isolates, 
diseased animals, China) to 11.1% (n=20/180, healthy animals, Vietnam).78–87 The qnrB 
gene was not detected either among isolates from healthy animals in Thailand (n=206) 
and Vietnam (n=180) but was found at very low prevalences in healthy and diseased 
animals in China (1.88%, n=426 and 1.97%, n=1679 respectively). 78–87 Additionally, 
none of 1,545 and 305 isolates from diseased and healthy animals respectively in China 




isolates from diseased animals but was found in 11/378 (2.91%) isolates from healthy 
animals in China. 78–87 Finally, qnrS was the most prevalent group of PMQR genes in 
Asia, with 18.1% of the isolates from healthy animals (n=62/426-China, 78/180-Vietnam, 
7/206-Thailand) and 12.3% of the isolates from diseased animals (n=196/1598, China) 
carrying this gene. 78–87 
 In addition to the general-EC isolates, the presence of qnr genes has been also 
investigated in certain resistant isolates. In South Korea, 5.74% (10/174) of FQ-resistant 
isolates carried qnrS gene while qnrA, qnrB and qnrD were not present in these 
isolates.88,89 In Denmark, none of the 39 FQ resistant isolates tested carried a qnrA, qnrB 
or qnrS genes.90 In China, 15.2% (n=30/198) and 22.2% (n=8/36) of the ESBL-EC and 
blaCTX-M carrying isolates respectively also carried qnrS gene.
64,91 The qnrD gene was 
also present in 6 of these 36 blaCTX-M isolates, whereas none carried qnrA, qnrB or qnrC 
genes.91 
Meta-analysis of factors affecting prevalences of antimicrobial resistance 
 
Overall, the mixed-effects meta-analytic regression model estimated a 5–9% annual 
increase (p<0.05) in the odds of general-EC isolates resistant to ceftiofur, cefotaxime and 
ceftazidime as well as for ESBL-EC isolates, whereas an annual 2-3% decrease in odds 
(p<0.05) was found in the percentage of colistin, NAL- and FQ- resistance in general-EC 
(table 2-14). 
In general, the odds of finding resistant general-EC were higher in isolates 
recovered from diseased pigs compared to healthy pigs/PMP: isolates recovered from 
diseased pigs were 1.4-6 times more likely to be resistant different antimicrobials 




odds of ESBL-EC isolation were non-significantly higher among E. coli isolates 
recovered from diseased pigs as compared to healthy pigs and porcine meat products 
(table 2-14). General-EC isolates collected from LMIC were 3-11% more likely to be 
resistant to different antimicrobials under study (p<0.01) and 1.41 (95% CI-1.12-1.77) 
times more likely to be ESBL-C as compared to isolates collected from UIC (table 2-14). 
Discussion 
 
The WHO has classified colistin and 3rd, 4th, and 5th generation cephalosporins as 
critically important drugs for human medicine. Similarly, the OIE has classified 
cephalosporins (1st, 2nd and 3rd generation) as critically important, and colistin as highly 
important, for veterinary medicine. Emerging patterns of resistance to both of these 
antimicrobial classes are among the most concerning issues surrounding AMR in human 
medicine, better understanding of the relevant epidemiology in animal reservoirs is 
desirable. The aim of this systematic review and meta-analysis was to integrate available 
global information on the prevalence and temporal patterns of resistance to key 
antimicrobials in indicator bacteria collected from sources of swine origin. In general, the 
prevalences of cephalosporin and colistin resistance were higher among isolates from 
LMIC countries compared to UIC countries. Prevalences of resistance were also higher 
among isolates collected from diseased pigs compared to isolates from healthy pigs or 
porcine meat products, except for prevalence of ESBL-EC. A wide repertoire of genes 
encoding resistance to cephalosporins, colistin and carbapenems have been identified 
among swine E. coli isolates.  
The range of cephalosporins used in food-producing animals is narrower than in 




for animal use since the 1970s, and some later generation cephalosporins were developed 
strictly for veterinary use.  Ceftiofur (3rd generation) is approved for use in many 
countries, while a fourth-generation cephalosporin (cefquinome) has been approved in 
the European Union and some other countries. In general, prevalences of cephalosporin 
resistance were higher in LMIC, which could be a consequence of the unregulated use of 
cephalosporins.92 Acknowledging the importance of cephalosporin resistance in human 
and veterinary medicine, preservation of this class of antimicrobials is a topic of debate 
among policy makers.93 The observed reduction in cephalosporin resistance in Danish 
isolates of food animal origin after the enforcement of a voluntary ban is an example of 
how policy making can mitigate the threat of extended spectrum cephalosporin 
resistance.94 Other measures that may mitigate cephalosporin resistance in animals 
include using third and fourth generation cephalosporins as second line of treatment and 
permitting their use only if indicated by antimicrobial susceptibility testing.95  
β-lactamases, including ESBLs, are the most important resistant mechanisms in 
Enterobacteriaceae and their corresponding encoding genes (bla genes) have served as a 
basis for their classification.96 Certain alleles of specific ESBLs families, including 
blaTEM, blaSHV and blaCTX-M , have been described as particularly successful.
97 Moreover, 
blaCTX-M family of genes can be sub-classified into specific allele types and the 
distribution of these alleles provide useful context to molecular epidemiology of ESBL 
resistance. Another common but non-ESBL genetic mechanism for third generation 





Genes belonging to the blaTEM family were found to be widespread in isolates 
collected from various swine sources. Widespread distribution of blaTEM genes among 
Enterobacteriaceae was already reported as early as 1970s, a concerning finding given 
that they can confer resistance to both penicillins and cephalosporins.99 However, blaTEM-
1, the most prevalent specific allele belonging to this blaTEM gene family, confers 
resistance to penicillins but not extended spectrum cephalosporins.99 Hence, the high 
prevalence of these genes alone in general-EC and ESBL-EC populations is not 
necessarily indicative of widespread 3rd and 4th generation cephalosporin resistance. 
 blaSHV genes have been cited to be widely displaced by the emergence of blaCTX-M 
and blaTEM genes in both human and animal populations.
100 In this systematic review, we 
also observed a comparatively low prevalence of blaSHV genes in ESBL-EC isolates 
collected from swine sources worldwide, with the exception of a few countries. However, 
unlike any of the blaCTX-M or blaTEM alleles, a blaSHV allele (blaSHV-38) has been able to 
confer resistance to carbapenems.101 Hence, the relatively lower prevalence of blaSHV 
genes should not understate their importance in conferring extended cephalosporin 
resistance. 
 blaCTX-M are a diverse group of genes that have undergone a rapid diversification 
and global dissemination post-2000 and are considered to be the dominant genetic 
mechanism behind the ESBL phenotype.102 Mirroring our results in swine, another 
systematic review found similar blaCTX-M genes to be globally prevalent in human 
isolates.103 However, these parallelisms in global distribution of blaCTX-M genes should 




reviews and research have found the directionality within these potential relationships to 
be unclear.104,105 
 The global spread of bacteria resistant to third and fourth generation 
cephalosporins has led to an increased consumption of last resort antimicrobials such as 
carbapenems in human medicine,106 which may lead to selection of other resistances such 
as those mediated by carbapenemases. Carbapenemases are β-lactamases capable of 
hydrolyzing not only carbapenems but also penicillins and third generation 
cephalosporins, and can be transmitted between different bacterial species via 
plasmids.107 It should be noted that carbapenems are not licensed for use in food in any 
country and hence, the risk factors behind the presence of carbapenem resistant in pigs or 
porcine meat products needs to be further evaluated.106 Although the phenotypic and 
genotypic prevalence of carbapenem resistance is extremely low, the significance of these 
results should not be understated. The widespread dissemination of carbapenem 
resistance is a relatively recent phenomenon as evidenced by the post-2010 changes in 
the extent and prevalence of carbapenem resistance in bacterial populations in European 
countries.108 Considering the mechanistic similarities in propagation and dissemination of 
extended spectrum cephalosporin and carbapenem resistance (such as plasmid mediated 
carriage of genetic elements, broad range substrate specificity, broad bacterial host range, 
etc.), carbapenem resistance could become established in bacterial populations as has 
been the case with resistance to extended spectrum cephalosporin in E. coli from swine. 
Carbapenem resistance has already become endemic in certain settings, such as the 




Italy,108 and therefore, there is an active need for assessing the risk of food borne sources 
such as swine products as a source of carbapenem resistance.109 
 Colistin is considered a last resort antibiotic for treatment of Gram-negative 
bacterial infections in human medicine.110 Colistin is widely used as a growth promotant 
in countries like India, and Vietnam, in addition as a treatment for digestive disorders in 
pigs.111 As a result, even low or moderate prevalences of phenotypic resistance in E. coli 
collected from swine sources should be a matter of significant concern. Previously, 
colistin resistance was thought to spread slowly via vertical transmission and with a slow 
pace of evolution, as this resistance was considered unstable and due to chromosomal 
mutations.14 However, recognition worldwide of plasmid mediated genes encoding 
colistin resistance has ignited the concerns in relation to several bacterial pathogens of 
humans.112 Our systematic review clearly documents the global distribution of plasmid 
mediated mechanism of colistin resistance in swine populations and porcine meat 
products. Readers are further referred to a review article wherein the authors discuss the 
public health implications, the pharmacology and use of colistin in pigs.113  
Since their discovery in the early 1960s, quinolones (such as nalidixic acid) and 
fluoroquinolones (such as ciprofloxacin) have played a critical role in both human and 
veterinary medicine.114  Fluoroquinolones are amongst the most commonly prescribed 
antimicrobials for treating urinary tract infections in humans115 and are also used 
worldwide for treatment for diseases in food animals such as bovine and respiratory 
diseased complex.116 In general, the prevalences of FQ-resistance were low in isolates 
from European and North American countries. However, there were certain exceptions, 




The prevalences of FQ- and NAL- resistance described here roughly correlate with 
consumption of FQs for those countries in which data was available: for example, the 
prevalences of FQ-resistance were higher in healthy and diseased animals from Spain and 
Portugal compared to countries such as Netherlands, Denmark and Sweden, in which the 
mg per population correction unit consumption of FQs is also lower.117 Similarly, the 
prevalence of FQ- and NAL- resistance was consistently low in Australia, a country 
where use of these antimicrobials has been banned in farm animals since before 2000.118 
This correlation between AMR and antimicrobial use in food animals at the country level 
has been already reported for FQ and other antimicrobial classes119 but should be 
interpreted with care due to the risk of ecological fallacies when analyzing grouped data.  
 In comparison to chromosomal mutations and efflux pump activity, PMQRs are a 
recent discovery, with the first true PMQR element (a qnr gene) being found in a human 
patient in 1998.36 Nevertheless, since then qnr genes have been found in plasmids 
varying in size and incompatibility specificity.36 qnr genes, transposable elements, 
plasmid incompatibility types and geographic spread have been recently reviewed in in 
detail by Hooper and Jacoby et al. (2015),35 that described the presence of qnr genes in 
bacteria of different origins in a far larger number of countries compared to those in 
present study. Hence, qnr genes might be present but undetected in swine populations or 
food products. Hence, more studies are needed to conclusively determine the spread of 
qnr genes in swine sources across several countries.  
 Co-resistance against multiple drug classes makes the problem of antimicrobial 
resistance in bacteria even more complex, as use of one class of antimicrobials can 




class.13 Quinolone and extended spectrum cephalosporin co-resistance has been reported 
in Gram-negative isolates collected from various sources in Canada, India and Italy.120–122 
Results from the current study also suggest that co-selection between FQ, NAL and 
extended spectrum cephalosporins is occurring at a varying level in swine isolates from 
various countries.  
 Across the studies we reviewed, clinical isolates were more resistant to 
quinolones, cephalosporins and colistin compared to isolates from healthy animals and 
porcine meat product. Some authors have suggested that treatment of diseased pigs 
before sample collection may lead to higher prevalences of AMR compared to healthy 
populations.95 Although AMR in clinical isolates is likely not representative of AMR in 
isolates from healthy swine populations, surveillance of AMR in clinical isolates can still 
be useful for monitoring purposes. In the absence of organized active surveillance 
programs, clinical submissions can be used as a passive surveillance system for 
monitoring levels of AMR, particularly against therapeutic agents such as quinolones, 
cephalosporins and colistin. This approach can be particularly useful in resource limited 
settings where diagnostic laboratories can play dual roles by enabling some AMR 
surveillance from routine diagnostic cases, although submission bias must be heeded. 
Importantly, clinical isolates can act as an early indicator of emerging resistance 
phenotypic and genotypic patterns.9 
 The pattern of higher prevalences of AMR in LMIC may be associated with the 
high levels of antimicrobial use in swine production in these countries.23 This problem 
may increase if, antimicrobial usage in food animal production increases in the upcoming 




surveillance in developing countries has been on human health, and AMR surveillance in 
food animal production has been largely ignored.124 It is advised that LMIC include food 
animal populations (including swine) in their AMR surveillance programs.  
Several limitations of this study must be borne in mind when interpreting the 
results. First, only articles written in English were included in the systematic literature 
review, thus potentially leading to the exclusion of data from many countries. Similarly, 
when estimating the changes of resistance over time and across geographical regions the 
different breakpoints (CLSI vs EUCAST epidemiological cut-offs) and laboratory 
methods (diffusion vs dilution methods, pooled vs non-pooled samples) used were not 
considered in the analysis due to the lack of consistent information. More robust 
estimates could be obtained using MIC or inhibition diameters for comparison of the 
resistance prevalences from different studies/regions/periods, but unfortunately the 
majority of the eligible articles reviewed did not provide the adequate quantitative 
information (distribution of MIC/inhibition diameters). 
Because the purpose of this study was to obtain estimates on the frequency of 
resistance to cephalosporins, carbapenems and colistin in E. coli of swine origin, articles 
focusing on single new/unusual genes, description of single plasmids or case reports and 
articles reporting data from a single farm/outbreak were not included. As a result, the 
reports of specific genes encoding resistance to the antimicrobials of interest of this 
review may have been missed if they were only reported very occasionally. Also, as 
reflected by the wide confidence intervals, there was considerable uncertainty around the 
estimates from certain countries/region/antimicrobials/sources where sample sizes were 




contrast, estimates from countries with an AMR surveillance program on E. coli of 
animal origin (e.g. European countries reporting to EFSA, Japan, South Korea or Canada) 
and larger sample sizes had less associated statistical uncertainty. Furthermore, the 
representativeness of the E. coli populations included in research-based studies will be 
typically lower than that of systematic surveillance programs, which underlines the 
importance of conducting guided surveillance programs to accurately estimate prevalence 
of antimicrobial resistance. 
Conclusions 
 
This study summarizes the existing evidence on prevalence of resistance to certain 
critical antimicrobials in E. coli isolates collected from various swine sources and 
describes some differences between periods and regions. The literature showed a 
moderate increase in antimicrobial resistance to selected critical antimicrobials over time, 
as well as differences in resistance levels in isolates collected from countries of different 
economic status, and across different sources of bacterial isolation. Genotypic resistance 
to critical antimicrobials was found to be prevalent globally. Although at a low level, 
carbapenem resistance was observed globally both phenotypically and genotypically. We 
hope that this review will serve as a useful baseline for both scientists and policy makers 
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Table 2-1. Characteristics of articles included in the literature review 
Characteristic of articles Sub-categories Number of articles 
(%) 
A) Continent from where 
isolates were recovered 
(n=324 articles) 
Europe 158 (48.8%) 
Asia 101 (31.2%) 
North America 43 (13.3%) 
South America 9 (2.77%) 
Africa 6 (1.85%) 
Australia 7 (2.16%) 
B) Year of publication 
(n=324 articles) 
1983-1999 8 (2.47%) 
2000-2005 49 (15.1%) 
2006-2010 68 (21.0%) 
2011-2015 113 (34.9%) 
2016- July 2018 86 (26.5%) 
C) Source of isolates 
(n=324 articles) 
Diseased pigs 117 (36.1%) 
Healthy pigs 154 (47.5%) 
Mixed (healthy and diseased) 
pigs 
12 (3.70%) 
Clinical status not defined 61 (18.8%) 
Porcine meat products 62 (19.1%) 




D) Laboratory methods 
used in articles with 
phenotypic data (n=300 
articles) 
Dilution 173 (57.7%) 
VITEK 2 (0.67%) 
Method not clear 2 (0.67%) 
E) Interpretive criteria used 
for classification of 
cephalosporin resistance 
(n=266 articles) 
CLSI 163 (61.3%) 
EUCAST  53 (19.9%) 
Others  11 (3.39%) 
None 40 (15.0%) 
F) Articles with genotypic 
information (n=109) 
Cephalosporin resistance 79 (72.5%) 
Colistin resistance 28 (25.7%) 




Table 2-2. Prevalence of ceftiofur resistance in general-EC isolates across different sources 
Country Healthy pigs Diseased pigs PMP References 
Argentina 6.10 (0-20.3) [21] 23.9 (13.5-36.3) [54] NA 125,126 
Australia 2.03 (0.01-6.21) [598] 21.02(0.14-59.54) [286] NA 77,127–131 
Austria 0(0-0.35) [744]  NA 132 
Belgium 2.53(1.49-3.77) [921] 1.26(0.1-3.24) [298] NA 133,134 
Brazil 2.5(0.77-4.94) [267] NA NA 45 
Canada 0.58(0.22-1.05) 
[16911] 
12.03(3.01-25.4) [1309] 1.21(0.5-2.13) 
[2977] 
135–161 
China 21.1 (12.3-31.4) 
[8469] 
43 (31.2-55.1) [1072] NA 54,64,72,86,91,162–168 
Czech 
Republic 




Denmark 0.31 (0.08-0.64) 
[3709] 
1.15(0.41-2.15) [1450] 0.57(0.06-1.4) [941] 26,57,132,170–176,176–192 
Estonia 4.24(1.33-8.38) [179] 3.09(0.31-7.81) [94] NA 132,191,193 
Finland 0.01(0-0.67) [526] 1.03(0-3.19) [258] NA 191,194–197 
France 0.53(0-3.07) [126] 2.6 (2.36-2.85) [20072] NA 191,198 
Germany 2.65(0-9.01) [53] NA NA 191,199 
Greece 1.15(0-4.5) [165] NA NA 200,201 
Iceland 0.69(0-3.64) [109] NA 1.14(0-6.53) [50] 202 
Ireland 0.61(0.08-1.45) [802] NA NA 11 
Italy 0.16(0-1.44) [269] NA NA 134 
Japan 0.3(0-1.09) [1191] NA NA 203–206 
South Korea NA 3.87(1-8.13) [575] NA 207–210 




Norway 0.11(0-0.9) [510] 1.04(0-3.62) [177] 0.23(0-1.69) [234] 191,212–214 
Poland 1.4(0-7.24) [692] NA NA 134,215 
Romania NA 22.34(0-71.81) [32] NA 216,217 
Serbia NA 5.33(1.11-11.89) [74] NA 218 
Spain 0.01(0-0.44) [757] 11.25(2.01-25.84) [332] NA 134,219 
Sweden 0(0-0.68) [284] 0.1(0-0.4) [3892]  NA 191,220,220–226 
Switzerland 1.05(0-3.36) [188] 0.39(0-3.32) [92] NA 134,191 
Taiwan 17.51(0-72.86) [711] NA NA 227 
Thailand 3.07(0-14.11) [23] 8.86(0-34.35) [170] NA 228 
USA 5.34(0.02-16.52) 
[4273] 
8.29(4.48-13.03) [5159] 14.52(3.75-30.18) 
[120] 
229–237 




Numbers outside bracket represent pooled percent prevalence of resistance. Numbers in round brackets represent 95% confidence 
interval of the estimate. Numbers in squared brackets represent the number of isolates tested. 
 
 
Table 2-3. Prevalence of cefotaxime resistance in general-EC isolates across different sources 
Country Healthy pigs Diseased pigs PMP References 
Australia NA 0.66(0-4.54) [70] NA 240 
Austria 0.76(0.16-1.64) [1012] NA NA 41,132,191,241–244 
Belgium 2.23(0.62-4.53) [548] NA NA 41,241,245 
Bulgaria 0.59(0.06-1.45) [1024] NA NA 41,246–249 
Cambodia 1.49 (0.07-4.08) [261] NA NA 250 
Canada NA 2.57(0.21-6.68) [112] NA 138 









Croatia 0.46(0-3.64) [85] 2.02(0-8.8) [370] NA 41,257,258 
Cuba NA 2.67(0-12.57) [26] NA 259 
Cyprus 5.57(0.8-13.46) [55] NA NA 41 
Czech 
Republic 
2.22 (0.06-6.39) [214] NA 3.75(0-1.348) [32] 41,75,76 
Denmark 0.57(0.16-1.13) [2046] 2.08(0.56-4.28) [311] 0.6(0-0.226) [258] 26,41,132,183–186,186–
188,190,192,241–244,260–263 
Estonia 5.67(1.97-10.85) [414] 3.47(0.48-8.39) [94] NA 41,191,191,193,242–244,264 
Finland 0.3(0-1.28) [1448] 4.06(2.08-6.56) [749] NA 41,191,196,197,243,265–267 
France 0.66(0.21-1.28) [1556] NA NA 132,191,241–244,244,260,261,263 
Germany 7.99(0-27) [1051] NA 2.43(0-0.934) [46] 41,242,260,261,268,269 




Grenada 0.04(0-1.41) [180] NA NA 270 
Hungary 1.11(0-3.41) [238] NA NA 41,241 






Ireland 0.38(0-2.54) [147] NA NA 41 
Italy 0.25(0-1.09) [567] NA NA 41,132,263 
Japan 1.32(0-7.29) [45] NA 2.79(0-1.304) [25] 279 
South Korea 0.37(0-4.1) [4381] 1.23(0-4.26) [130] NA 209,280–282 
Latvia 0.09(0-1.81) [150] NA NA 41 
Lithuania 0.42(0-3.45) [89] NA NA 41 
Malaysia 9.86(0-37.93) [7] NA NA 283 









NA  295 
Norway 0.77(0-3.11) [918] NA 2.55(0-1.212) [27] 41,132,191,242,296 
Poland 1.6(0.79-2.61) [1426] NA NA 41,241,242,244,297 
Portugal 2.34(0-7.36) [264] NA NA 41,298 
Romania 0.97(0.09-2.42) [399] NA NA 41 
Slovakia 0.46(0-3.64) [85] NA NA 41 
Slovenia 0.46(0-3.64) [85] NA NA 41 
South 
Africa 
15.8 (4.97-30.8) [169] NA NA 299 




Sweden 0.17(0-0.71) [1452] 0.44(0-1.99) [269] NA 27,41,132,191,221,242,262,263,303 
Switzerland 0.28(0-0.93) [902] 0.27 (0-2.54) [119] NA 41,241–244,304 
Taiwan 2.5(0.06-7.2) [360] NA NA 227 
Thailand 32.7 (0-86.5) [724] 10.4(5.58-16.37) [131] NA 48,78,228,305,306 
UK 0.05(0-1.52) [170] 0.16(0-1.64) [205] 1.16(0-0.525) [79] 41,307,308 
Numbers outside bracket represent pooled percent prevalence of resistance. Numbers in round brackets represent 95% confidence 
interval of the estimate. Numbers in squared brackets represent the number of isolates tested. 
 
Table 2-4. Prevalence of ceftazidime resistance in general-EC isolates across different sources 
Country Ceftazidime resistance 
in healthy pigs 
Ceftazidime resistance 
in diseased pigs 
Ceftazidime 
resistance in food 
products 
References 




Australia 1.78 (0.46-3.70) [325] 0.73(0-3.57) [114] NA 127,128 
Austria 0.75(0-2.56) [303] NA NA 41,241 
Belgium 1.95(0.74-3.57) [548] NA NA 41,241,245 
Bulgaria 0.69(0.11-1.56) [1024] NA NA 41,246–249 
Cambodia 2.82 (0.10-8.0) [261] NA NA 250 
China 2.89(0.33-7.25) [997] 12.5 (0.68-34.07) 
[509] 
NA 54,56,67,86,91,163,252,309 
Croatia 0.55(0-3.76) [85] NA NA 41 
Cyprus 5.69(0.91-13.56) [55] NA NA 41 
Czech 
Republic 
1.3(0.03-3.72) [187] NA NA 41 




Egypt NA NA 62.66(49.93-74.57) 
[59] 
310 
Estonia 5.28(1.69-10.42) [218] NA NA 41,242,243,264 
Finland 0.03(0-1.18) [217] NA NA 41 
France 0.7(0.18-1.46) [1023] NA NA 41,191,241–244 
Germany 0.91(0-3.75) [991] NA 2.55(0-9.45) [46] 41,242,269,311 
Greece 3.82(0.97-8.09) [159] NA NA 41,200 
Grenada 0.08(0-1.52) [180] NA NA 270 
Hungary 2.89(0-9.44) [183] NA NA 41 
India NA 99.9(98.36-100) [170] NA 274 
Ireland 0.47(0-2.65) [147] NA NA 41 
Italy 0.27(0-1.46) [317] NA NA 41,191 
South Korea 0.77(0-3.58) [4013] 3.11(0.25-8.2) [204] NA 209,280,312–314 




Lithuania 0.51(0-3.57) [89] NA NA 41 
Malaysia 9.97(0-37.96) [7] NA NA 283 
Malta 0.8(0-4.81) [68] NA NA 41 





13.03(0-47.46) [5] NA 295,315 
Norway 0.17(0-1.03) [462] NA NA 41,242 
Poland 1.12(0.34-2.2) [1242] NA NA 41,241,242,297 
Portugal 2.46(0.02-7.48) [264] NA NA 41,298 
Romania 1.08(0.16-2.54) [399] NA NA 41 
Slovakia 0.55(0-3.76) [85] NA NA 41 






13.3 (3.36-28.0) [169] NA NA 299 
Spain 0.48(0.06-1.17) [1174] NA NA 41,242,244,300–302 
Sweden 0.05(0-1.32) [200] NA NA 41 
Switzerland 0.44(0.03-1.14) [902] 0.27 (0-2.54) [119] NA 41,241–244,304 
Taiwan 0.39(0-1.58) [360] 1.8(0-7.06) [61] NA 227,316 
Thailand 18.5 (0.52-51.21) 
[724] 
3.61(0.89-7.71) [131] NA 48,78,228,305,306 
UK 0 (0-0.38) [2650] NA NA 41,317 
Vietnam 3.16(0-13.05) [323] 0.25(0-2.38) [126] NA 79,239,318 
Numbers outside bracket represent pooled percent prevalence of resistance. Numbers in round brackets represent 95% confidence 





Table 2-5. Prevalence of phenotypic ESBL resistance in general-EC isolates across different sources 
Country Healthy pigs Diseased pigs PMP References 
Austria 1.46(0.02-4.22) [163] NA NA 41 
Belgium 0.21(0-1.87) [186] 9.86(0-37.93) [7] NA 41 
Brazil 2.5(0.77-4.94) [267] NA NA 45 
Bulgaria 3.4(0-15.35) [21] NA NA 41 






Croatia 0.46(0-3.64) [85] NA NA 41 
Cyprus 5.57(0.8-13.46) [55] NA NA 41 
Czech 
Republic 




Denmark 4.21(1.89-7.26) [4684] NA 0.56(0.11-1.21) 
[1213] 
26,41,94,185–188,325 
Estonia 1.04(0-4.84) [85] NA NA 41 
Finland 0.13(0-0.67) [1374] NA 0(0-0.61) [303] 41,265,267 
France 0.17(0-1.7) [200] NA NA 41 
Germany 3.44(1.23-6.5) [212] 2.12(0.56-4.37) [2187] NA 41,326–328 
Greece 4.89(1.48-9.82) [116] NA NA 41 
Hong Kong 79.34(72.86-85.17) 
[172] 
NA NA 329 
Hungary 0.8(0-3.11) [170] NA NA 41 
India 16.3 (7.25-28) [1045] 25.07(18.74-31.96) 
[170] 
NA 274,275,330,331 
Ireland 0.38(0-2.54) [147] NA NA 41 




Japan 1.76 (0.01-5.4) [1225] NA 2.79(0-13.04) [25] 51,279,333,334 
South Korea 18.8 (9.76-29.8) [59] 1.95 (0.1-5.31) [585] NA 209,335,336 
Latvia 0.09(0-1.81) [150] NA NA 41 
Lithuania 0.42(0-3.45) [89] NA NA 41 
Malaysia 9.86(0-37.93) [7] NA NA 283 
Malta 0.7(0-4.69) [68] NA NA 41 
Netherlands 13.1 (7.64-19.8) 
[2713] 
NA 0.3(0-0.91) [1538] 41,284–286,337 
Nigeria 31.42(27.7-35.25) 
[600] 
NA NA 338 
Norway 0.27(0-0.91) [905] NA NA 41,339–341 
Poland 3.49(0.02-10.71) [422] NA NA 41,342,343 




Romania 0.97(0.09-2.42) [399] NA NA 41 
Slovakia 0.46(0-3.64) [85] NA NA 41 
Slovenia 0.46(0-3.64) [85] NA NA 41 
Spain 27.07(0-99.19) [199] NA NA 41 
Sweden 0.46(0-1.47) [1139] NA 0.2(0-1.21) [486] 27,41 
Switzerland 7.58 (2.84-14.1) [354] NA 1.14(0-6.53) [50] 41,347–351 
Taiwan NA 19.29(14.74-24.26) 
[275] 
NA 352 
Thailand 58 (28-85.1) [664] 11.93(6.79-18.19) 
[131] 
NA 48,52,228,319,353 






Vietnam 19.1 (0-87) [163] NA 31.82(24.44-39.67) 
[147] 
50,318,355 
Numbers outside bracket represent pooled percent prevalence of resistance. Numbers in round brackets represent 95% confidence 
interval of the estimate. Numbers in squared brackets represent the number of isolates tested. 
 
Table 2-6. Pooled estimates of percentage prevalence of bla and mcr-1 genes in general-EC populations 


























































































































NA NA NA 74 























NA NA 303 
Switzerland NA 7.75(0.7-
20.3) [29] 






































Numbers outside bracket represent pooled percent prevalence of resistance. Numbers in round brackets represent 95% confidence 










Table 2-7. Pooled estimates of percentage prevalence of select bla genes in ESBL-EC isolates and isolates resistant against extended 
spectrum cephalosporins 
Country blaSHV blaCTX-M blaCMY blaTEM References 










NA NA 45 
Cambodia 13.0 (0-47.5) [5] 13.0(0-
47.5) [5] 
NA NA 319 





















Denmark 15.3(0-54.1) [4] 29.2(0.71-
74.3) [4] 
15.3(0-54.1) [4] NA 325 
Finland 8.89(0-34.5) [8] 8.89(0-
34.5) [8] 
8.89(0-34.5) [8] 8.89(0-34.5) 
[8] 
267 








 Hong Kong NA 42.2(32.0-
52.7) 
[368] 













NA NA 332 
Japan NA 96.6(85.2-
100) [22] 
NA NA 51 
Netherlands NA 99.9(99.1-
100) [259] 
NA NA 337 









































Thailand 3.64(0-12.3) [64] 68.4(16.7-
100) [64] 
NA NA 48,319 














*- This data is based on isolates resistant against extended spectrum cephalosporins (ceftiofur)  
Numbers outside bracket represent pooled percent prevalence of resistance. Numbers in round brackets represent 95% confidence 




Table 2-8. Global percent prevalence of specific blaCTX-M alleles in ESBL-EC isolates 
blaCTX-M alleles Global percent 
prevalence of 
specific alleles 










Prevalence of specific 
alleles in Asian countries 
among ESBL-EC 
(number of isolates with 
specific allele/total 
number of isolates) 
Prevalence of specific alleles 
in European countries among 
ESBL-EC (number of 
isolates with specific 
allele/total number of 
isolates) 













blaCTX-M-2 2.70 (7/259) Netherlands - 2.70 (7/259) 




1.29 (5/387) 1.66 (3/181) 
blaCTX-M-9 32.5 (126/388) Hong Kong, 
India, Portugal, 
Spain 
47.7 (104/218) 12.9(22/170) 




















15.6 (91/585) 7.56 (40/529) 
blaCTX-M-22 2.99 (5/167) China 2.99 (5/167) NA 
blaCTX-M-24 0.67 (1/149) China, Germany 1.16 (1/86) 0 (0/63) 
blaCTX-M-27 5.19 (18/347) China, United 
Kingdom 




blaCTX-M-28, 36, 69 0 (0/167) China 0 (0/167) NA 
blaCTX-M-32 1.35 (6/443) Netherlands, 
Portugal, United 
Kingdom 
NA 1.35 (6/443) 
blaCTX-M-55 1.44 (90/624) China, Japan, 
Taiwan, United 
Kingdom 
18.5 (88/475) 1.34 (2/149) 
blaCTX-M-64 2.02 (4/198) China 2.02 (4/198) NA 
blaCTX-M-65 12.1 (46/381) China, South 
Korea, Taiwan 
12.1 (46/381) NA 
blaCTX-M-97 12.7 (8/63) Germany NA 12.7 (8/63) 
blaCTX-M-104 2.02 (4/198) China 2.02 (4/198) NA 
blaCTX-M-123 3.03 (6/198) China 3.03 (6/198) NA 





Table 2-9. Global prevalence of carbapenem resistance in general-EC isolates 
Country Number of isolates 
tested for carbapenem 
resistance 




Australia 509 2 127,128,240 
Austria 163 0 41 
Belgium 186 0 41 
Bulgaria 21 0 41 
Cambodia 261 0 250 
China 805 11 54,60,61,67,163,253,254 
Croatia 85 0 41 
Cyprus 55 0 41 
Czech 
Republic 
187 0 41 




Estonia 85 0 41 
Finland 1146 0 41,265 
France 279 0 41 
Germany 661 4 41,55 
Greece 167 6 41,381 
Grenada 180 0 270 
Hungary 170 0 41 
India 112 23 382 
Ireland 147 0 41 
Italy 168 0 41 
Japan 92 0 279 
South Africa 169 3 299 
South Korea 599 10 207,312 
Spain 186 0 41,69,301,302 




Latvia 150 0 41 
Lithuania 89 0 41 
Malaysia 7 0 283 
Malta 68 0 41 
Netherlands 2159 3 41,284–286,291–294 
Norway 270 0 41 
Poland 170 0 41 
Portugal 264 1 41,298 
Romania 399 0 41 
Slovakia 85 0 41 
Slovenia 85 0 41 
Sweden 200 0 41 
Thailand 654 2 78,353 





Table 2-10. Prevalence of colistin resistance in general-EC isolates across different sources 
Country Healthy pigs Diseased pigs PMP References 
Australia 0.04 (0-0.91) [325] NA NA 127 
Austria 0.3(0-2.2) [163] NA NA 41 
Belgium 0.28 (0-1.28) [443] 9.21(5.02-14.39) [157] NA 41,245,383 
Brazil NA 22.7 (10.1-38.4) [300] NA 384–387 
Bulgaria 3.4(0-15.35) [21] 5.91(3.01-9.6) [220] NA 41,388 
Cambodia 16.3 (4.27-33.6) [261] NA NA 250 
China 28.9 (21-37.3) [10500] 4.55(0-27.9) [1018] NA 64,65,72,168,256 
Croatia 0.46(0-3.6) [85] 2.1(0.62-4.2) [370] NA 41,257,258 
Cyprus 0.98(0-5.9) [55] NA NA 41 
Czech 
Republic 




Denmark 0.1 (0.01-0.29) [6025] 0.75(0.24-1.45) [1835] 0.61(0.13-1.31) [1200] 26,41,170–190,260,261,389 
Estonia 1.43(0-4.37) [156] NA NA 41,264 
Finland 0(0-0.32) [782] 2.84(0.08-8.1) [76] NA 41,265,266 
France 0.15(0-0.57) [6193] NA NA 41,260,261,360,390 
Germany 1.1 (0.32-2.21) [2853] NA NA 41,260,261,361 
Greece 0.72(0-3.4) [159] NA NA 41,200 
Hungary 0.71(0-3.26) [210] NA NA 41 
Ireland 0.1(0-1.86) [147] NA NA 41 
Italy 1.67 (0-6.13) [550] NA NA 41,63 
Japan 0.38(0.01-1.1) [1375] 34.36(3.37-76.08) [802] NA 203–206,363,391–393 
South 
Korea 
0.81(0.32-1.45) [3514] 17.43(2.81-40.01) [664] NA 207,208,364,394 




Latvia 0.36(0-2.5) [150] NA NA 41 
Lithuania 1.42(0-4.36) [149] 1.72(0-7.07) [60] NA 41,211 
Malaysia 9.86(0-37.93) [7] NA NA 283 
Malta 0.7(0-4.69) [68] NA NA 41 
Netherlands 0.02(0-0.32) [2023] NA 1.16(0-3.88) [519] 260,261,284–288 
Norway 0(0-0.75) [270] NA NA 41 
Poland 0.05(0-1.52) [170] NA NA 41 
Portugal 2.09(0.34-4.83) [198] NA NA 41 
Romania 0.09(0-0.97) [399] NA NA 41,216 
Serbia NA 33.76(23.35-45) [74] NA 218 
Slovakia 0.46(0-3.64) [85] NA NA 41 
Slovenia 0.46(0-3.64) [85] NA NA 41 




Sweden 0.03(0-0.84) [367] 1.39(0.05-3.84) [269] 3.59(0-16.06) [20] 27,41,220,221,303 
Numbers outside bracket represent pooled percent prevalence of resistance. Numbers in round brackets represent 95% confidence 
interval of the estimate. Numbers in squared brackets represent the number of isolates tested. 
 
 
Table 2-11. Prevalence of fluoroquinolone (FQ) resistance in general-E isolates across different sources 
Country Healthy pigs Diseased pigs PMP References 
Argentina 11.9 (6.26-19.0) [104] 57.1 (43.7-70.1) [54] NA 125,126,397,398 
Australia 1.37 (0.40-2.73) [535] 0.09 (0-1.16) [295] NA 127,128,130,131,240,399 
Austria 3.13 (2.08-4.34) [1526] NA NA 41,132,191,241–244 
Belgium 5.41 (0.89 -12.7) 
[1615] 
4.01 (0.73-9.20) [431] NA 41,133,134,241,245 




Bulgaria 5.37 (1.62 -10.8) 
[1024] 
18.8 (13.8-24.3) [220] NA 41,246–249,388 
Cambodia 40.6 (5.98 -81.9) [261] NA NA 250 
Canada 0 (0-0) [21420] 6.16 (0-22.1) [510] 0 (0-0.30) [2977] 135,136,139,140,142–146,148–
161,401,402 
Chile 7.71 (3.93-12.5) [187] NA NA 251,403 






Croatia 6.89 (2.25-13.5) [85] 21.9 (15.7-28.9) [370] NA 41,257,258 
Cuba NA 0.32 (0-7.38) [26] NA 259 
Cyprus 43.7 (30.8-57.0) [55] NA NA 41 
Czech 
Republic  
1.47 (0.10-3.83) [214] 3.61 (0.37-9.16) [80] 6.85 (0.47-18.4) 
[32] 
41,75,76,169 









Egypt NA NA 47.5 (34.8-60.3) 
[59] 
310 
Estonia 7.16 (0.9 -17.4) [403] 20.5 (1.03-53.4) [94] NA 41,132,191,193,242–244,264 
Finland 0.77 (0.19-1.62) [917] 12.6 (6.74-19.7) 
[1364] 
NA 194–197,265,266,407 






Germany 1.71 (0 -6.11) [1382] NA 6.76 (1.06-16.1) 
[46] 
41,191,199,242,260,261,269,311 
Greece 5.81 (1.35-12.6) [281] NA 15.8 (7.0-27.2) 
[51] 
41,200,201,381 
Grenada 0 (0-0.56) [180] NA NA 270 
Hungary 9.57 (5.82-16.3) [238] NA NA 41,241 






India 27.9 (13.7-44.9) [393] 9.40 (6.78-12.4) [454] NA 271,272,276–278,408–410 
Ireland 2.09 (0.55 -4.32) [949] NA NA 11,41 
Italy 6.86 (1.99 -14.0) [836] NA NA 41,134,191,263 
Japan 0.96 (0 -2.96) [1359] 10.4 (0.15-30.6) [118] 20.7 (7.17-38.5) 
[25] 
203–206,279,392,411 
Latvia 4.95 (1.83-9.23) [150] 22.4 (9.51-38.7) [31] NA 41,134 
Lithuania 5.30 (0.05-16.0) [149] 23.6 (7.19-45.3) [109] NA 41,211,412,413 
Malaysia 17.8 (0.15-51.5) [7] NA NA 283 
Malta 5.84 (1.25-12.9) [68] NA NA 41 






0 (0-0.16) [296] NA NA 416 
Nigeria 7.13 (3.02-12.6) [121] 96.3 (65.7-100) [5] NA 295,315 




Poland 9.07 (6.44-12.1) [2118] NA NA 41,134,215,241,242,244,297 
Portugal 8.97 (0-34.9) [264] 49.9 (25.1-74.8) [122] NA 41,134,298 
Romania 29.3 (24.9-33.9) [399] 78.3 (63.8-89.9) [38] NA 41,216,217 
Serbia NA 25.7 (16.8-35.8) [82] NA 218,417 
Slovakia 6.89 (2.25-13.5) [85] NA NA 41 
Slovenia 5.01 (0.06-15.1) [115] NA NA 41 
South 
Africa 
21.7 (2.88 -50.4) [169] NA NA 299 
South 
Korea 
14.0 (7.50-22.0) [4556] 48.5 (27.5-69.9) [731] NA 88,207,208,210,280–282,312–
314,394 
Spain 33.3 (11.7-59.3) [3200] 42.4 (20.0-66.6) [672] 0 (0-0.89) [180] 41,69,132,134,191,219,242,244,260–
262,300–302,418,419 
Sweden 3.65 (0.24-9.75) [1385] 5.70 (4.66-6.83) 
[5977] 
3.25 (0-15.8) [20] 27,41,132,220–226,262,263,303,415 




Taiwan NA 85.2 (75.1-93.2) [61] NA 316 
Thailand 48.7 (21.1-76.7) [1372] 15.4 (0-81.8) [251] NA 48,78,228,305,306,366,422,423 
Uganda NA 0 (0-1.47) [100] NA 424 
United 
Kingdom 






0 (0-0) 1963] 0 (0-0) [5159] 6.25 (1.58 -13.3) 
[120] 
229–231,233–237 
Vietnam 24.3 (10.5-41.4) [443] 14.6 (0-69.0) [187] 16.1 (3.38-35.1) 
[20] 
79,238,239,318,425 
Numbers outside bracket represent pooled percent prevalence of resistance. Numbers in round brackets represent 95% confidence 







Table 2-12. Prevalence of nalidixic acid (NAL) resistance in general-EC isolates across different sources 
Country Healthy pigs Diseased pigs PMP References 
Argentina 32.6 (22.9-43.1) [83] NA NA 397,398 
Australia 1.87 (0-20.8) [9] 2.77 (0.06-7.99) [77] 0 (0-1.07) [142] 240,399,426 
Austria 2.49 (1.65-3.46) 
[1756] 
NA 2.35 (0.42-5.38) 
[179] 
41,132,191,241–244,427 
Belgium 6.11 (2.42-11.1) 
[1615] 
24.9 (18.2-32.3) [431] NA 41,133,134,241,245 
Brazil 24.6 (17.7-32.2) [141] NA NA 400 
Bulgaria 24.6 (8.79-44.8) [21] NA NA 41 
Cambodia 20.6 (11.1-31.9) [261] NA NA 250 
Canada 0 (0-0) [20230] 0.38 (0-2.51) [150] 0.05 (0-0.33) 
[3165] 
142–146,148–161,402,428 




China 68.1 (41.2-89.9) 
[1056] 
91.9 (75.3-100) [1243] NA 64,85,91,162,167,252,254,309,404,405 
Croatia 10.4 (4.64-18.0) [85] 31.0 (25.4-36.9) [256] NA 41,257 
Cuba NA 12.3 (2.41-27.7) [26] NA 259 
Cyprus 21.9 (11.9-33.9) [55] NA NA 41 
Czech 
Republic  
0.61 (0-2.48) [24] NA 9.95 (1.82-22.8) 
[32] 
41,75,76 








Estonia 3.32 (1.66 -5.43) [414] 30.8 (17.3-46.2) [94] NA 41,132,191,193,242–244,264 
Finland 2.13 (0.72 -4.08) 
[1207] 
20.8 (14.6-27.6) [493] NA 41,191,194–197,243,265,266 
France 3.0 (2.14-3.96) [1654] NA NA 41,132,191,241–244,263 






Greece 7.22 (3.94 -11.3) [281] NA NA 41,200,201 
Hungary 5.55 (2.57 -9.42) [693] NA NA 41,132,241 
Iceland 12.6 (6.87-19.7) [109] NA 8.16 (1.95 -17.6) 
[50] 
202 
India 74.8 (47.3-94.6) [387] 39.3 (3.49-84.0) [540] NA 271,272,276–278,409,410 
Ireland 1.66 (0.04-4.73) [147] NA NA 41 
Italy 7.16 (3.18-12.4) [836] NA NA 41,134,191,263 
Japan 2.58 (1.24-4.29) 
[1961] 
34.5 (22.5-47.6) [118] NA 203–206,391–393,411 
Latvia 3.61 (0.98 -7.46) [150] 35.2 (19.5-52.8) [31] NA 41,134 
Lithuania 7.68 (2.84-14.4) [89] 35.0 (22.3-48.8) [49] NA 41,412,413 
Malaysia 97.5 (74.1-100) [7] NA NA 283 
Malta 4.36 (0.52-10.8) [68] NA NA 41 
Netherlands 0.72 (0.13-1.61) 
[3566] 






Nigeria 1.78 (0-12.7) [231] 15.5 (0-53.3) [57] NA 295,431 
Norway 0 (0-0.23) [1043] 0.20 (0 -1.91) [177] 0 (0-0.48) [579] 41,132,191,212–214,242,296 
Poland 6.05 (4.70-7.53) 
[2202] 
NA NA 41,132,134,215,241,242,244,297 
Portugal 8.76 (5.51-12.6) [264] 84.5 (70.2-94.9) [33] NA 41,134,298 
Romania 15.6 (12.1-19.4) [399] NA NA 41 
Slovakia 6.89 (2.25-13.5) [85] NA NA 41 
Slovenia 8.04 (0-50.4) [115] NA NA 41 
South 
Africa 





55.9 (25.0-84.5) [160] NA 207,208,280 
Spain 18.1 (14.5-22.1) 
[2907] 




Sweden 0.58 (0.06-1.42) 
[1248] 
NA 0.56 (0-9.67) 
[20] 
41,132,191,220,242,263 
Switzerland 3.23 (2.14-4.50) 
[1090] 
25.9 (19.8-32.4) [245] NA 41,191,241–244,304,421 
Taiwan NA 95.1 (87.9-99.4) [61] NA 316 
Thailand 70.8 (30.7-97.9) [576] NA NA 48,305,422 
Uganda NA 8.77 (3.82-15.3) [100] NA 424 
United 
Kingdom 




1.45 (0-5.26) [1963] 0 (0-1.71) [230] 23.9 (4.04 -52.6) 
[120] 
229,230,233–237 
Vietnam NA NA 30.6 (12.7-52.1) 
[20] 
425 




Numbers outside bracket represent pooled percent prevalence of resistance. Numbers in round brackets represent 95% confidence 
interval of the estimate. Numbers in squared brackets represent the number of isolates tested. 
 






Brazil 100 (8) NA 45 
Canada 0 (85) 0 (85) 371 
China 63.2 (429) 82.4 (318) 64,321–323,372 
Germany 28.7 (286) 42.7 (75) 46,47,326 
Hong Kong 27.2 (206) 68.4 (206) 329 
Japan 13.6 (22) 40.9 (22) 51 
South Korea 77.8 (9) 88.9 (9) 336 
Portugal 17.1 (35) 28.6 (35) 346 




Switzerland 0 (9) 66.7 (9) 368 
Taiwan 100 (54) 94.4 (54) 352 
Thailand 44.4 (54) 52.2 (134) 48,52 
Vietnam 12.8 (39) 23.1 (39) 50 
Numbers outside bracket represent raw percentage of ciprofloxacin or NA- resistance in ESBL-EC isolates. Numbers inside the round 







Table 2-14. Changes in prevalence of AMR based on the random-effects model including 
time (years), source of isolates, and income levels of countries as fixed effects and 
country as a random effect 
Antimicrobial/ ESBL-EC Odds ratio p-value 
a) Cefotaxime   
Time 1.09 (1.07-1.12) <0.01 
Diseased (reference=Healthy/PMP) 1.76 (1.48 -1.09) <0.01 




Time 1.05 (1.03-1.06) <0.01 
Diseased (reference=Healthy/PMP) 4.25 (3.80-4.77) <0.01 




Time 1.05 (1.03 -1.08) <0.01 
Diseased (reference=Healthy/PMP) 1.04 (0.85-1.26) 0.71 




Time 1.09 (1.05 -1.13) <0.01 
Diseased (reference=Healthy/PMP) 1.35 (0.94-1.94) 0.10 








Diseased (reference=Healthy/PMP) 5.96 (5.02 -7.08) <0.01 
LMIC (reference=UMIC) 5.97 (2.25-15.91) <0.01 
f) NAL-resistance   
Time 0.98 (0.97-0.99) <0.001 
Diseased (reference=Healthy/PMP) 4.49 (4.10-4.93) <0.001 
LMIC (reference=UMIC) 3.58 (1.52-8.46) 0.004 
g) FQ-resistance   
Time 0.98 (0.97-0.99) <0.001 
Diseased (reference=Healthy/PMP) 1.60 (1.50-1.70) <0.001 























































































S 2-1. Search strings used in systematic review: 
Pubag- ((antibiotic or drug or antibacterial or antimicrobial or colistin or polymyxin or 
lactamase or beta or quinolone or fluoroquinolone or carbapenemase) and (resistance or 
susceptibility) and (pig or sus or porcine or swine) and (escherichia coli or e coli)) 
Web of science- ((TS=((antibiotic or drug or antibacterial or antimicrobial or colistin or 
polymyxin or lactamase or beta or quinolone or fluoroquinolone or carbapenemase) and 
(resistance or susceptibility) and (pig or sus or porcine or swine) and (escherichia coli or 
e coli)))) AND LANGUAGE: (English) 
Pubmed- (("Drug Resistance"[Mesh]) or "Polymyxins"[Mesh]) AND "Swine"[Mesh] 
AND "Escherichia coli"[Mesh] ) 
CABI- ((antibiotic or drug or antibacterial or antimicrobial or colistin or polymyxin or 
lactamase or beta or quinolone or fluoroquinolone or carbapenemase or spectrum) and 
(Pig or Swine or Porcine or Sus) and (resistance or susceptibility or resistant) and 






















CHAPTER-3 Prevalence and time trend analysis of antimicrobial 
resistance in clinical Escherichia coli isolates collected from diseased 




In the last few decades, antimicrobial resistance has emerged as one of the most 
important problems affecting veterinary and human medicine. Antimicrobials have been 
the cornerstone of modern medicine, and the emergence of widespread antimicrobial 
resistance (AMR) could lead to a post-antimicrobial era in which common infections and 
minor injuries would be deadly once again.30 Use of antimicrobials in animal production 
systems has been implicated as one of the causes for increased prevalence of resistant 
bacteria such as Escherichia coli, non-typhoidal Salmonella etc. in both animals and 
humans, and it is considered a major food safety issue. 38,438 
Pork makes up 36% of the world’s meat supply and USA is the world’s third 
largest producer and consumer of pork (USDA). Antimicrobials are used in swine 
industry worldwide for various purposes including growth promotion, prevention and 
treatment of diseases.3 In USA, nearly 37% of medically important antimicrobials sold in 
food animals are used in swine production.439 Since antimicrobial use in pigs can also 
select for resistant zoonotic bacteria, AMR in zoonotic bacteria of swine origin are also 
of interest to public health.11  
 Escherichia coli is a commensal microorganism typically found in the intestinal 
tract of mammals and it has the potential to be pathogenic in humans and animals when it 
harbors certain virulence genes or possess other traits such as lower fitness costs.440 




isolation and its ability to easily gain and disseminate genetic elements (including AMR 
determinants) makes this bacterium a suitable candidate to monitor the prevalence of 
AMR over time.37  
Due to the potential public health and animal health impacts of antimicrobial use 
in animal production systems, Food and Drug Administration (FDA) has recently taken 
initiatives to phase out the use of medically important antimicrobials as growth promoters 
in animal production effective January 2017.6 Discontinuity on the use of growth 
promoters is expected to contribute to a decrease in the prevalence of antimicrobial 
resistant bacteria in food animals, as observed in Europe when the use of growth 
promoters was banned.95 However, to assess the success of changes in such policies, 
information on the long-term baseline prevalence of AMR in food animals is required. 
Passive surveillance using veterinary diagnostic laboratory data provides a low-cost 
alternative to studying prevalence and trends of AMR in food animals.441 The Veterinary 
Diagnostic Laboratory at the University of Minnesota (MNVDL) receives thousands of 
clinical samples of swine origin every year coming from all the major pork producing 
states in the USA, and it can be considered as a source of information regarding AMR in 
bacteria circulating in swine in the country.  
 The objective of this study was to describe the prevalence and trends of the 
phenotypic AMR in E. coli of swine origin isolated from clinical samples at the MVDL 
between 2006-2016. The antimicrobials studied herein are of importance to both animals 
(e.g. phenicols, tetracyclines etc.) and humans (e.g. analogues of fluoroquinolones, 




results of this study will help in informing evidence-based antimicrobial stewardship in 
order to improve animal and human health. 
 




 E. coli isolates collected from clinical samples of swine origin submitted to the MVDL 
for diagnostic purposes from January 2006 to December 2016 were included in the study. 
These included samples varying from whole swine carcasses for necropsy, tissue or fecal 
samples and body fluids such as urine and semen. Multiple samples could be received 
from a single epidemiological unit (e.g. carcasses of piglets who have died at the same 
farm from diarrhea) and these samples were labelled with a single accession number. 
Swabs collected from samples were used to inoculate sheep blood agar and MacConkey 
agar plates that were incubated at 370 C for 18-24 hours. Colony morphology and 
presence/absence of hemolysis was noted, and a single colony per morphology was 
selected and streaked on a new MacConkey agar plate for incubation as described above. 
Bacterial colonies from the second MacConkey agar plate were used for antimicrobial 
susceptibility testing.  
 Antimicrobial susceptibility testing of all isolates was performed by the broth 
microdilution method using the Sensititre automatized dilution system (Trek Diagnostic 
Systems, Cleveland, OH) to determine the minimum inhibitory concentration (MIC) 
according to the CLSI standards (CLSI, VET01-A4). Only antimicrobials for which at 
least 100 isolates were tested annually over the 2006-2016 period were included in this 
analysis: Ampicillin (AMP, range-  0.25-16 µg/ml), Ceftiofur (XNL, range-  0.25-8 




0.125-2 µg/ml), Florfenicol (FFN, range-  0.25-8 µg/ml), Gentamycin (GEN, range- 1-16 
µg/ml), Neomycin (NM, range- 4-32 µg/ml), Oxytetracycline (OTC, range-  0.5-8 
µg/ml), Spectinomycin (SPT, range- 8-64 µg/ml), Sulphadimethoxine (SDM, range- 256-
>256 µg/ml) and Trimethoprim-Sulphamethoxazole (SXT, range- 2->2 µg/ml).  
 Selection of E. coli isolates for antimicrobial susceptibility testing and virulence 
profiling was based on bacterial morphology, discretion of diagnostic pathologist and/or 
request of the submitting client. Usually, one E. coli isolate per accession number was 
screened for antimicrobial susceptibility testing, particularly if all isolates from the 
accession had similar morphological characteristics. Beta-hemolytic E. coli isolates were 
preferentially selected because they have been associated with clinical disease in neonatal 
and post-weaning pigs. However, if there were multiple bacterial morphologies or if the 
clinical history of the pigs submitted within the same accession differed, multiple E. coli 
isolates could be selected for antimicrobial susceptibility testing.  
Statistical analysis 
 
 Analyses were carried out at the isolate level. To avoid overrepresentation of the same E. 
coli strains, only one isolate per AMR profile and submitting client per month were 
selected for the analysis. Only isolates for which information on the date of submission 
(later categorized as season), age of the pig (age categories or exact age) and hemolytic 
nature (yes/no) (table S3-1) was available were included in the study. Isolates were 
classified as resistant or non-resistant based on breakpoints provided by CLSI and 
National Antimicrobial Resistance Monitoring Systems (NARMS) or epidemiological 
cut-offs provided by EUCAST (table S3-2). Isolates categorized as intermediate by 




analyses, MIC values below/above the dilution ranges were rounded to the next serial 
dilution immediately before/after respectively.    
Univariate analysis- Hierarchical logistic regression models with a logit link function 
were fitted for each antimicrobial using the binary AMR response as the outcome 
variable (resistant or non-resistant) and the time (in years), season, age and hemolytic 
nature as independent variables (package “lme4”, R). Geographic state of origin of the 
sample were included in all models as random effects to account for the lack of 
independence between observations. The time associated odds ratios were estimated by 
exponentiating the coefficient for the time (in years) variable and the odds ratio at 
average prevalence levels were subsequently converted to risk ratios to estimate the 
percent annual change in prevalence of resistance to individual antimicrobials (package 
“sjstats”, R).442 
Analyses of multiple antimicrobial resistance (MAR)- MAR was studied using various 
statistical approaches- regression analysis, diversity index (richness of AMR 
combinations per year) and network analysis. For regression models, an isolate was 
classified to be multiple antimicrobial resistant if it was resistant to 3 or more different 
antimicrobial classes. Antimicrobials belonging to same class were grouped together in 
one class and the isolate was considered resistant to that antimicrobial class if it was 
resistant to at least one of the antimicrobials in that class. (CTET and OT), (GEN and 
NM) and (SXT and SDM) were grouped together as tetracyclines, aminoglycosides and 
sulphonamides, respectively. Hierarchical logistic regression model with logit link were 
built with MAR as binary outcome variable and time (in years) as continuous 




independent fixed-effects variables and submitting client and geographical state as 
categorical, random effect variables. Rarefaction curves were built to estimate the 
richness or number of unique combinations of phenotypic resistances (resistotypes) per 
year after rarefying to control for uneven number of isolates analyzed annually (package 
“vegan”, R).  
 For the network analysis approach, MIC data were analyzed using Gaussian 
graphical model. This is a type of undirected graphical probabilistic model which has 
been used to estimate partial correlations between AMRs using MIC values directly and 
plotting them for easy graphical inferences, as previously described using “Rnets” 
package in R.12 Briefly, MIC values for each year were first converted into empirical 
correlation matrices using Spearman’s rank correlation method. These matrices were then 
transformed into penalized precision matrices based on a regularization parameter λ, 
which reduces certain correlations to zero and hence, produces sparser but more 
interpretable networks. These penalized precision matrices were then plotted graphically 
in the form of a network wherein the vertices represent the antimicrobials and the edges 
represent the penalized (weighted) partial correlations. The selection of λ was done using 
the stability approach to regularization selection method for each year. Stability scores 
for various values of λ (ranging from 0.05 to 0.60 in 0.05 increments) were evaluated for 
each year. The smallest λ that had a stability statistic (D) <0.10 was selected to estimate 
penalized correlation matrices for each year.  
 The global network strengths of these graphical models were then compared using 
network comparison tests using the package “Network Comparison Test” in R. MIC 




strengths were calculated as the weighted absolute sum of all edges in a regularized 
partial correlation network under various permutations and pairwise comparison between 
AMR networks from different years were compared. p-values were adjusted using the 
linear step-up method as previously described to decrease false discovery rates due to 
multiple testing (PROC MULTTEST, SAS).  
Results 
 
General description of data 
 
There were 9697 isolates with complete information on age, state of origin of the animal 
from which the sample originated, date of submission, hemolytic characteristics and 
susceptibility results for all antimicrobials under study. On average, 881 isolates were 
retrieved every year (range- 434-1115 per year). The main characteristics of the isolates 
are provided in table S3-1. Nearly 48% of the isolates were collected from nursery pigs, 
followed by pre-weaning pigs (37%). Frequency of isolation was nearly equal across all 
four seasons. Nearly two-thirds (62%) of the isolates were beta-hemolytic. Overall, 
isolates were collected from accessions submitted by 242 unique clients (swine systems, 
veterinary clinics) spread over 35 states across USA. Nearly 39% (n=4196) isolates were 
collected from Minnesota. The geographic distribution of isolates collected from states 
other than Minnesota are presented in table S3-3.  
Univariate analysis 
 
Raw change in prevalences to antimicrobials are presented in figure 3-1 and results from 
hierarchical logistic regression models are presented in table 3-1. The antimicrobials 
evaluated here could be divided in four groups, based on the percentage of resistant 
isolates found. For ampicillin, chlortetracycline, oxytetracycline and sulphadimethoxine, 




for subtle changes, the percentage of isolates resistant to chlortetracyline and 
oxytetracycline remained nearly constant. However, the percentage of isolates resistant to 
AMP increased from ~67% between 2006-13 to ~75% by 2016. In contrast, the 
percentage of resistant isolates to SDM decreased from 81% in 2006 to 65% in 2016 
(annual decrease in prevalence-3%, p<0.01).  
The prevalence of SPT resistance averaged at 40.5% and this prevalence 
decreased consistently from 49.4% in 2006 to 37.1% in 2016 (annual decrease in 
prevalence -3%, p<0.01). The percentage of isolates resistant to florfenicol, gentamicin, 
trimethoprim-sulphamethoxazole and ceftiofur ranged between 18-40% during the study 
period (figure 3-1), with values fluctuating over the years, except for florfenicol 
resistance which decreased steadily from 31% in 2007 to 19.5% in 20-15 (annual 
decrease in prevalence -3%, p<0.01). Finally, in the case of enrofloxacin, a steady 
increase in the percentage of resistant isolates was observed between 2006 (~1%) and 
2016 (21%) (annual increase in prevalence-39%, p<0.01).   
Analyses of MAR 
 
Up to 264 (2.7%) and 1,136 (11.7%) of the isolates were either fully susceptible to all 
antimicrobials or resistant to only one antimicrobial class, respectively. Overall, there 
were 122 unique resistotypes. The top ten resistotypes, which accounted for up to 57% of 
the isolates (n=5,531) are shown in table 3-2. The mean and median number of 
antimicrobial classes that the isolates were resistant to was 3.81 and 4, and these numbers 
remained nearly constant across the years. However, based on rarefaction curve, the 
number of unique resistotypes increased consistently from 43.8 in 2006 to 69.4 in 2016 




There were 6,956 (72%) isolates which were resistant to ≥ 3 antimicrobial classes. 
Based on a hierarchical logistic regression model, the percentage of isolates resistant to 3 
or more antimicrobial classes decreased by 1.71% annually (95% CI- 0.36 to 3.05%) (p-
value=0.01).  
  The optimum λ-value based on the stability statistic (first D value < 0.10) 
varied across years and was 0.30, 0.35 and 0.40 for 6 years, 5 years and 1 year, 
respectively. The number of edges per year in the networks based on different values of λ 
are presented in figure 3-3 and an increase in the number of edges over the years can be 
seen in AMR networks regardless of λ-value. Networks built with λ-value=0.3 are 
presented in figure 3-4 and these networks were used for comparative purposes below.  
At the value of λ=0.3, 22 unique edges were found out of possible 45 edges 
(48.9%) across all years. The mean density of the networks was 27.3%, ranging from 
20% in 2007 and 2009 to 35.6% in 2015. The average number of closed triplets (3 AMR 
nodes connected to each other) was 2.4 per network for 2006- 2010 and increased to an 
average of 6.83 per network for 2011-2016. Furthermore, there were sub-graphs of 4 
AMR nodes interconnected to each other in years 2011, 2014 and 2015. For 2016, 5 
AMR nodes (GEN-NM-SDM-SPT-SXT) were interconnected to each other and there 
were 11 closed triplets in that year. The most common closed triplets were GEN-SPT-
SXT (years 2006, 2010-2016), GEN-NM-SXT (years 2008, 2011, 2012, 2014-2016), 
SDM-SPT-SXT (years 2011-2016) and AMP-FFN-XNL (years 2006, 2009-2012). 
Comparison of networks revealed that there were no statistically significant differences in 
network strengths between 2006-2010 (figure 3-4). Significant differences (p<0.05) in 




2008-2012, 2007-2013, 2008-2013, 2007-2014, 2008-2014, 2007-2016 and 2008-2016 
(figure 3-4).   
Discussion 
 
The objectives of this study were to describe the prevalence and evolution of AMR in E. 
coli isolates recovered from swine clinical samples submitted to the MVDL between 
2006-2016. Prevalence of resistance to certain antimicrobials such as tetracyclines, 
ampicillin, sulphamethoxazole was found to be high throughout the period of study 
(>50%). There was either a modest decrease or increase in prevalence of resistance to all 
antimicrobials, except for prevalence of enrofloxacin resistance which increased 
drastically during the study period. Similarly, the proportion of isolates resistant to more 
than 3 antimicrobial classes decreased modestly but the networks of MARs became 
denser and resistotype richness increased over time.  
 The prevalences of ampicillin and gentamicin resistances in our study were 
similar to those found in swine clinical E. coli isolates from Ontario, Canada and 
Australia but prevalence of ceftiofur resistance was higher in our study as compared to 
these studies (Canada- 10-20%, Australia- 0%).130,443 The prevalence of neomycin 
resistance in this study was higher than in the United Kingdom (18%) but lower than in 
Australia (42%).130,308 The prevalence of resistance to other antimicrobials 
(sulphonamides, tetracyclines) was similarly found to be high (>50%) in swine clinical E. 
coli isolates from Australia, Canada, France, Italy and the United Kingdom.130,198,308,443,444 
Also, prevalences of florfenicol and spectinomycin resistance in current study were 
similar to those estimated in Denmark and Canada.190,443 Considering that sulphonamides, 
tetracyclines and penicillins are estimated to be among the top classes of antimicrobials 




countries, the high prevalence of resistant isolates found here might be potentially 
correlated with their consumption in food animals.119,161,439  
Similar to our study, the prevalence of ceftiofur, potentiated sulphonamides, 
gentamicin and tetracycline resistance did not change significantly or changed only to a 
modest extent in clinical swine E. coli isolates from Canada and France over a long 
period of time, suggesting that the resistance to certain key antimicrobials has remained 
stable worldwide including USA.198,443 The prevalence of AMRs also seldom remained 
constant and fluctuated greatly over short time in these studies. Using a shorter timeframe 
for AMR trend analysis could lead to raising of false alarms. Currently, EFSA comducts 
trend analysis on AMR data collected for 5 years or more.445   
 Fluoroquinolones such as enrofloxacin are classified as critically important for 
human health30 and are also effective for treating several bacterial infections in 
animals.446 The percentage of resistance to enrofloxacin increased among the E. coli 
evaluated here rapidly from 1% in 2006 to 21% in 2016 (39% increase annually). These 
results are similar to that what has been described in swine clinical E. coli isolates from 
several European countries, but considerably higher than that from Australia and Canada, 
where nearly 0% of isolates are enrofloxacin resistance (Chapter-2). A drastic increase in 
enrofloxacin resistance was also reported in Salmonella spp. isolates in USA447 and E. 
coli isolates in Italy.444 In USA, enrofloxacin was labelled for use as a treatment of swine 
respiratory disease complex in 2008 and enteritis in 2012447, thus suggesting that the 
increase in resistance may be linked to its use in swine medicine.  
 The problem of AMR is further compounded by the phenomena of co-resistance 




multiple mobile genetic elements or chromosomal mutations (Canton and Ruiz-
Garbajosa, 2011).448 Similar to our study, patterns of co-resistance to penicillin-
sulphonamide-other antimicrobials and tetracycline-sulphonamide-other antimicrobials 
were reported to be common in swine clinical E. coli isolates from Sweden and Denmark, 
respectively.190,303 Additionally, AMR networks revealed potential correlations between 
resistances to different antimicrobials such as ceftiofur-florfenicol, enrofloxacin-
trimethoprim-sulphamethoxazole etc. These co-resistances can have practical 
implications on control of AMR as use of one antimicrobial class can select for an 
unrelated antimicrobial class, which can have consequences on policies relying on 
restriction of antimicrobial usage.448 Sundqvist et al. (2010) cited co-resistance with 
multiple antimicrobials as one of the reasons behind persistence of trimethoprim-
sulphamethoxazole resistance in E. coli despite drastic reduction in its use in human 
populations in the UK.449 Several field trials have demonstrated the correlation between 
resistance to an antimicrobial and use of an unrelated antimicrobial in animal production 
systems.11,450  
 There was a slight annual decrease in proportion of isolates resistant to more than 
3 antimicrobial classes but there was an increase in resistotype richness over time 
implying an increase in the number of co-resistance patterns over the years. An increase 
in density of AMR networks further proves that the correlations between resistances to 
muktiple antimicrobials have increased statistically. The differences in results using 
logistic regression and network analysis can be explained by loss of information due to 
dichotomization of AMR results when evaluating the evolution in AMR.451 




been a common method to characterize and study changes in MAR.452 Considering that 
multivariate networks approach uses the complete spectrum of MIC values and provides 
information about biological relationships between different AMRs, we recommend 
using this approach in conjunction with the traditional methods (logistic regression). 
However, biases can be induced in the interpretation of the network analysis method used 
in this study as the results are highly sensitive to value of λ used. As a result, it is 
recommended that data on the density of networks based on different values (figure 3-3) 
should be provided along with the network graphs. 
 There are a few key points that must be considered before making inferences 
based on this study. First, the MVDL represents a passive surveillance system and hence, 
there are inherent biases in the samples received here, such as higher number of isolates 
from Minnesota, preferential selection towards hemolytic E. coli strains, etc. that can 
potentially affect the generalizability of the results. Secondly, the isolates are typically 
collected from diseased animals which might have been treated with antimicrobials prior 
to being sampled. Indeed, the prevalence of AMR in our study is considerably higher 
than that in E. coli isolates collected from healthy pigs at slaughter between 2013-16.453 
As such, this study should not be interpreted as an analysis of clinical efficacy of these 
antimicrobials in the field. Lastly, there is a need to correlate these prevalences and trends 
in AMRs with actual antimicrobial usage data. Availability of antimicrobial usage data in 
swine production medicine and field trials to study effects of using antimicrobials on co- 
and cross-selection of AMR in USA can help to clarify the possible role of antimicrobial 




 Despite these important limitations, we believe this study provides valuable 
information in several ways. Despite the difference in levels of prevalences between our 
data and E. coli isolates collected from pigs at slaughter during active surveillance 
(NARMS), the rank order of prevalence of different AMRs is similar in both datasets e.g. 
penicillins, tetracyclines and sulphonamide are also the top three resistances in NARMS 
data.453 It has been postulated that analyzing trends in AMR using passive surveillance is 
beneficial and more powerful in detecting early, emerging but rare AMRs as compared to 
active surveillance.9 Indeed, the emergence and rapid increase in fluoroquinolone 
(enrofloxacin) resistance in this study preceded the emergence of fluoroquinolone 
resistance in Salmonella spp. isolates collected from healthy swine and retail pork by 
NARMS.454 Hence, passive surveillance of AMR can serve as an important ancillary tool 
to the active surveillance programs.  
Conclusion 
 
In conclusion, our study elucidated changes in patterns of AMR in swine clinical E. coli 
isolates collected over more than a decade. For the antimicrobials included in this study, 
prevalence of AMR remained constant or changed modestly, except for enrofloxacin 
resistance. However, emergence in enrofloxacin resistance, persistence of high 
prevalences of AMR to ampicillin, sulphadimethoxine and tetracyclines and increase in 
resistotype richness and density of AMR networks over the years could be a cause of 
concern for controlling AMR in swine. These results can help in guiding surveillance of 
AMR in swine production and conservation of antimicrobials’ efficacy by informing 
judicious use of antimicrobials. However, the lack of associated antimicrobial usage data 




antimicrobial usage data with results of AMR prevalence and field trials are needed to 
study the extent of co-resistance in selection of AMR in actual production settings.  
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Range of annual 
percentage 
resistance 
Risk ratio* (95% CI) 
Ampicillin 68.1 63.3-75.4 1.01 (1.01-1.02) 
Ceftiofur 34.1 
 
29.8-39.1 0.99 (0.98-1.0) 
Enrofloxacin 8.50 0.2-21.5 1.39 (1.35-1.44) 
Florfenicol 24.1 19.5-31.0 0.97 (0.96-0.98) 
Gentamicin 23.9 17.5-29.2 1.02 (1.01-1.04) 
Neomycin 33.8 25.6-40.2 0.98 (0.97-0.99) 
Spectinomycin 40.5 49.4-35.6 0.97 (0.96-0.97) 
Sulphadimethoxine 71.6 65-83.3 0.97 (0.97-0.98) 
Oxytetracycline 92.8 90.6-95.8 1.0 (0.99-1.0) 
Trimethoprim-
Sulphamethoxazole 
22.0 18.2-28.6 1.01 (1.0-1.02) 
Chlortetracycline 82.0 78.1-89.0 1.0 (0.99-1.0) 
Numbers in bold were significant at p<0.05 
*- Risk ratio was obtained by converting odds ratio associated with time (in years) at 




season, hemolytic characteristics and age as other fixed effects and geographic state of 
collection as random effect. 
 
Table 3-2. Most common resistotypes 
Resistotype Number of 
isolates 

























Figure 3-1. Changes in prevalence of AMRs over years 
 
Vertical axis represents percentage of resistant isolates, horizontal axis represents the year of isolation, legend on the right represents 
antimicrobials tested- AMP (ampicillin), XNL (ceftiofur), CTET (chlortetracycline), ENR (enrofloxacin), FFN (florfenicol), GEN 
























































Figure 3-2. Rarefaction curve displaying number of unique phenotypes per year 
 
Vertical axis represents the number of unique resistotypes estimated by rarefaction. 
Horizontal axis represents the number of isolates for which this estimation was rarefied. 
The vertical line in the middle starts at sample size 434 on horizontal axis, which is the 
least number of isolates collected for a year (2007). This line represents the number of 
resistotypes for different years if all the years has same sample size (n=434 isolates). 
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Figure 3-3. Changes in number of edges of multivariate networks of AMRs based on 

























































Value of λ 
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Figure 3-4. Multivariate networks of AMR  
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Table S3-1. Brief characteristics of isolates studied 




11 years  
Percentage of total isolates 
(Range of isolates belonging 
to this category over years) 
a) Age 
   
Fetus Aborted material 180 1.96 (0.56-3.08) 
Pre-weaning 0-21 days old 3599 37.0 (33.3-41.9) 
Nursey 22-77 days old 4630 49.9 (42.2-52.9) 
Growing-
Finishing 
78- 197 days old 1166 11.8 (8.52-15.6) 
Adult  <197 days old 122 1.36 (0.78-1.95) 
b) Season 
   
Winter January-March 2529 26.2 (23.4-30.3) 
Spring April-June 2845 28.5 (25.1-39.7) 
Summer July-September 2168 22.0 (19.4-28.2) 
Fall October-
December 
2155 23.3 (8.72-27.0) 
c) Hemolysis 




6042 62.6 (56.2-67.2) 
Hemolytic 
 




Table S3-2. Breakpoints used for classifying isolates 
Antimicrobial Breakpoints Source 
Ampicillin ≤ 16  32 CLSI Vet08 4th edition, humans; 
NARMS 
Ceftiofur ≤ 4  8 CLSI Vet08 4th edition, swine 
(respiratory infections); NARMS 
Enrofloxacin ≤ 1  2 CLSI Vet08 4th edition, poultry 
Florfenicol ≤ 8  16 CLSI Vet08 4th edition, swine 
(respiratory infections) 
Gentamicin ≤ 4  8 CLSI Vet08 4th edition, humans; 
NARMS 
Neomycin ≤ 8  16 Epidemiological cut-offs 
(EUCAST) 
Spectinomycin ≤  32 >64 Epidemiological cut-offs 
(EUCAST) 
Sulphadimethoxine ≤ 256 > 256 Hong et al. (2016); NARMS 




≤ 2 > 2 Hong et al. (2016); NARMS 





Figure S3-1. Geographic distribution of isolates  
 
 
Horizontal axis represents the geographical location of E. coli isolation in USA (MO-
Missouri, IL-Illinois, OK-Oklahoma, NC-North Carolina, Others-Other states, KS-
Kansas, NE-Nebraska, CO-Colorado, OH-Ohio, TX-Texas, AR-Arkansas, SD-South 
Dakota, WI-Wisconsin). Vertical axis represents the overall number of E. coli isolates 





























CHAPTER-4 Prevalence and time trend analysis of antimicrobial 





Respiratory diseases are frequently associated with substantial financial losses in swine 
production systems worldwide due to high morbidity, decreased weight gain, increased 
culling rates, and additional medicine and labor costs.455 Etiology of respiratory diseases 
is often complex, with a group of bacteria (such as Actinobacillus pleuropneumoniae) 
and viruses acting as primary pathogens with potential to cause the disease alone and 
other microorganisms (such as Pasteurella multocida, Haemophilus parasuis and 
Streptococcus suis) acting as secondary pathogens that further aggravate the disease.456 A. 
suis and H. parasuis are members of the Pasteurellaceae family and are associated with 
systemic diseases including polyserositis, pleuritis, meningitis, arthritis, and respiratory 
diseases such as acute pneumonia.457 P. multocida are commensal bacteria that can act as 
opportunistic secondary pathogens during respiratory diseases caused by other agents 
such as Mycoplasma hyopneumoniae.458 S. suis is a Gram-positive bacteria that primarily 
causes septicemia, but that can also contribute to the swine respiratory disease complex 
(SRDC) as a secondary pathogen.459  
 Management practices, vaccination, and antimicrobial therapy are the main 
methods available to prevent, treat, and/or control infection caused by those pathogens. 
These bacteria are commensals that colonize pigs early in their life, so that subclinically 
infected pigs can act as sources of infection for other susceptible pigs.460–463 Hence, 
management strategies aimed at preventing their circulation in a herd can be difficult to 
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execute in practice due to their widespread presence. The effect of vaccination in 
preventing and controlling infections due to these bacterial pathogens has so far proven 
inconsistent because of the wide serotype diversity of the bacteria involved, poor cross-
protection, low protective efficacy, and interference with maternal antibodies.464–467   
 Because of the challenges in preventing infection with these ubiquitous pathogens 
through management measures and the inefficacy of vaccination, use of antimicrobials 
plays a key role in the control of SRDC. A number of antimicrobial compounds from 
different classes have been licensed for SRDC treatment, including penicillins 
(ampicillin, penicillin), cephalosporin (ceftiofur), tetracyclines (oxytetracycline, 
chlortetracycline), macrolides (tulathromycin), and pleuromutilins (tiamulin). Use of 
antimicrobials has been linked to the eventual development of resistance in bacteria,468  
and therefore there is a need for its judicious use to preserve their efficacy.116 
Surveillance of antimicrobial resistance (AMR) plays an important role in ensuring the 
long-term efficacy of antimicrobials but, unlike AMR in Escherichia coli and Salmonella 
enterica, which is routinely monitored as part of the National Antimicrobial Resistance 
Monitoring Systems (NARMS), little information is available regarding AMR trends in 
SRDC pathogens in USA.469  
The surveillance of AMR in swine bacterial pathogens is further compounded 
because of the lack of clinical and epidemiological cut-offs that allow the classification of 
isolates as susceptible/resistant or wild type/non-wild type for several bacteria-
antimicrobial combinations.470 To circumvent this problem, clinical breakpoints of 
related bacterial species or newly set cut-offs are often used.116 However, harmonization 
and standardization of AMR data across studies is difficult to achieve. 
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The objectives of this study were to estimate the prevalence of, and changes over 
time in AMR to antimicrobials in swine bacterial pathogens (A. suis, H. parasuis, P. 
multocida and S. suis) in the U.S. using antimicrobial susceptibility testing results from 
the University of Minnesota-Veterinary Diagnostic Laboratory (UMN-VDL) through a 
decade (2006-2016). The antimicrobials tested for susceptibility are commonly used in 
swine medicine in the U.S. Minnesota is the third largest pork producing state and the 
UMN-VDL routinely receives diagnostic submissions from all the major pork producing 
states in the U.S., resulting in an alternative source of data for analyzing AMR in swine 
pathogens in the absence of formal systems to collect such information in the country. 
Results here will help to elucidate the trend of AMR in SDRC in the U.S, which, 
ultimately, will help to inform decisions related with the prevention and control of one of 
the syndromes that results in the largest financial impact for the swine industry of the 
country. 




Data on the antimicrobial susceptibility testing performed on bacteria associated with the 
SRDC recovered from swine samples submitted for routine diagnostic purposes to the 
UMN-VDL between January 1, 2006 to December 31, 2016 (A. suis, P. multocida and S. 
suis) and January 1, 2010 to December 31, 2016 (H. parasuis) was used in this study. 
Samples consisted on tissue sections or swabs and were cultured on tryptic soy agar with 
5% sheep blood aerobically with and without 5% CO2 for 18-24 hours for bacterial 
isolation except in the case of H. parasuis isolation, for which sheep blood agar plates 
were additionally supplemented with a streak of Staphylococcus aureus that acted as a 
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source of a required factor (nicotinamide adenine dinucleotide) needed for H. parasuis 
growth. Bacterial colonies were characterized at the bacterial species level by standard 
biochemical testing and/or MALDI-TOF mass spectrometry.  Minimum inhibitory 
concentrations (MIC) were determined by the broth microdilution method using the 
Sensititre automatized dilution system (Trek Diagnostic Systems, Cleveland, Ohio). A 
range of dilutions was tested for a number of antimicrobials. Antimicrobial susceptibility 
testing of S. suis and P. multocida isolates was performed as per the standardized Clinical 
and Laboratory Standards Institute (CLSI) methodology.471 MIC values for A. suis and H. 
parasuis were determined by growing standardized quantities of bacterial suspensions on 
cation-adjusted Mueller Hinton broth and Haemophilus test medium respectively for 18-
24 hours at 35-370 C aerobically with 5% CO2. Quality control was maintained following 
CLSI guidelines.471 
Data extraction and statistical analysis 
 
Antimicrobial susceptibility data, along with information on the age of the pig, date of 
isolation, organs from which the bacteria were isolated, and geographical state of origin 
were extracted from the computerized database maintained at the UMN-VDL. Because 
multiple isolates of the same bacterial species were collected from samples submitted by 
the same client, only isolates with unique MIC value-combinations for all antimicrobials 
were selected per submitting client for further analyses.  
S. suis and P. multocida isolates were classified as “resistant” or “non-resistant” 
to specific antimicrobials using CLSI breakpoints when available (tables 4-1). For those 
antimicrobials for which swine specific CLSI breakpoints were not available, breakpoints 
applicable to other species (humans, cattle) or epidemiological cut-offs (gentamicin- P. 
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multocida) were used, if available (tables 4-2 and 4-3). There were no breakpoints or 
epidemiological cut-offs available for A. suis and H. parasuis. MIC50 and MIC90, the 50
th 
and 90th percentile of the MIC distributions respectively, were also estimated and 
presented in tables 4-2, 4-3, 4-4 and 4-5. 
Changes in AMR levels over time were estimated for each bacteria-antimicrobial 
combination using logistic regression models. Specifically, the status of bacterial isolates 
(resistant or non-resistant) was used as a binary dependent variable and time (in years) as 
a continuous independent variable of interest as described elsewhere.472,473 Models also 
accounted for the association with variables such as organ or system of isolation 
(respiratory or other organs such as liver, joints, heart etc.), season (winter, fall, spring 
and summer), and state of origin (Minnesota or elsewhere in the U.S.), which were added 
as categorical fixed effects. Changes in AMR prevalence over time were quantified using 
the exponential of the coefficient for the time variable, referred to as “time associated 
odds ratio” from here onwards.  
For those antimicrobial- bacterial species combinations for which dichotomization 
of antimicrobial susceptibility results was not possible due to the lack of available 
breakpoints, ordinal regression models were built. In these models, the dependent 
variable was the MIC value of the isolates, while accounting for the association with the 
independent variables previously described. Because change across time was the output 
of interest, the results of the model outputs may be interpreted as the odds of being at a 




For these ordinal regression models, the proportional odds assumption was 
statistically tested474 and if the assumption was not met, non-proportional odds ordinal 
logistic regression models were fitted. Due to convergence issues, MIC values ranging 
from 2-5 dilutions were binned together if needed. A primary difference between a 
proportional and non-proportional odds logistic regression models is that the former 
provides a single odds ratio for all levels and it is more parsimonious as compared to the 
latter, which provides a separate time associated odds ratio for each MIC level. The 
results of the abovementioned models are summarized in the tables S4-1, S4-2, S4-3 and 
S4-4. 
Because breakpoints and epidemiological cut-offs were not available for A. suis 
and H. parasuis, authors have resorted to using cut-offs defined by themselves or using 
clinical breakpoints from bacteria of family Pasteurellaceae (Actinobacillus 
pleuropneumoniae and Histophilus somni) to analyze antimicrobial susceptibility results 
of H. parasuis (table 4-6). The impact of using different breakpoints on the interpretation 
of prevalence and trends in AMR data for A. suis and H. parasuis was assessed by 
estimating the percentage of resistant isolates and building the binary logistic regression 
models previously described. The agreement between AMR prevalence estimates 
calculated using different breakpoints were statistically evaluated using unbiased Kappa 
coefficient and prevalence-associated bias-associated Kappa (PABAK) coefficients.475 
PABAK coefficients greater than 0.75, between 0.50-0.74 as fair and less than 0.50 were 







Description of data 
 
Overall, 20,230 isolates were analyzed in this study. Nearly 66% of those isolates were 
either S. suis or P. multocida and 6.5 % of the isolates were H. parasuis. Nearly 74, 80 
and 88% of the A. suis, H. parasuis and P. multocida isolates were obtained from the 
respiratory tract, whereas 90% of the S. suis isolates with AMR data available were 
collected from organ systems other than respiratory system. The majority (45%) of the 
isolates were collected from diagnostic samples submitted by clients in Minnesota. 
Isolates from the rest of the top ten pork producing states in USA made up for 45% of the 
isolates. Age information was available for 84% of the isolates, of which 78% were 




Briefly, breakpoints were available for 8 antimicrobials tested in >7,000 isolates, and 
prevalence of resistance to 6 of them was below 10% (table 4-2). In fact, the overall 
prevalence of resistance to five antimicrobials (ampicillin, ceftiofur, enrofloxacin, 
florfenicol and trimethoprim-sulphamethoxazole) was low (<3%) (table 4-2) and ranged 
between 0-3% across the years. The overall prevalence of penicillin resistance was 7.0% 
and varied from 5.3% in years 2006-09 to 9.7% in years 2013-16 (9% annual increase in 
odds, p<0.01). Levels of oxytetracycline and chlortetracycline resistance were always 
high and ranged between 93-97% over the years.  
 Breakpoints were not available for gentamicin, spectinomycin, tiamulin, 
tulathromycin and sulphadimethoxine and MIC distributions for these antimicrobials are 
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presented in table 4-2. There was a 10-17% annual increase in the odds of being at higher 
MIC values (4 µg/ml) as compared to lower MIC values for gentamicin (p<0.01) (figure 
4-1a). For sulphadimethoxine, there was a modest 4% decrease in odds of having MIC 
value of >256 µg/ml over the years (p<0.01). For tulathromycin, there were no 
statistically significant annual changes in odds of having different MIC values. The 
results were inconclusive for spectinomycin and tiamulin, with both statistically 
significant annual increases and decreases in odds for some MIC values for these 
antimicrobials. For example, in case of spectinomycin, there was a 7% annual decrease 
(p<0.01) and 3% annual increase (p<0.01) in odds of having MIC values 32 µg/ml and 
128 µg/ml as compared to lower MIC values, respectively.  
Pasteurella multocida 
 
Breakpoints were available for 10 antimicrobials tested in > 8000 isolates, with overall 
AMR prevalence being less than 10% and annual values ranging between 0 to 8% in 8 of 
them (ampicillin, ceftiofur, enrofloxacin, florfenicol, gentamicin, penicillin, 
spectinomycin and tulathromycin) (table 4-3). Resistance against the remaining two 
antimicrobials (oxytetracycline and chlortetracycline) varied widely and ranged between 
28-56% (chlortetracycline) and 52-72% (oxytetracycline) during the study period, with 
logistic regression models suggesting a modest (4-6%) annual increase in the odds of 
resistance (p<0.01).  
Breakpoints were not available for tiamulin, sulphadimethoxine and 
trimethoprim-sulphamethoxazole and MIC distributions for these are provide in table 4-3. 
For tiamulin, there was a statistically significant annual decrease (2-8%) in the odds of 
having MIC values 4 µg/ml as compared to lower MIC values. There was a modest 
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annual increase (3%) in odds of having sulphadimethoxine MIC value of >256 µg/ml 




There were no breakpoints available for any of the antimicrobials for A. suis and detailed 
MIC distributions are presented in table 4-4. There was no statistically significant change 
in the odds of having different MIC values for enrofloxacin, trimethoprim-
sulphamethoxazole and gentamicin. There was a statistically significant annual decrease 
of 15-29% in the odds of having higher MIC values for ceftiofur (0.5 µg/ml), 
spectinomycin (16 µg/ml), sulphadimethoxine (>256 µg/ml) and tiamulin (1 µg/ml) as 
compared to lower MIC values (figures 4-1b, c, d). For ampicillin, there was a 
statistically significant (p<0.05) yet modest decrease (4-7%) in the odds of being at MIC 
values 0.5 µg/ml as compared to baseline MIC value of 0.25 µg/ml. The change in odds 
of being at different MIC levels were less uniform and inconclusive for oxytetracycline, 
florfenicol, tulathromycin and penicillin compared to other antimicrobials, with either a 
statistically significant increase or decrease at some MIC levels but non-significant 
changes at other MIC values. Similarly, the change in odds for chlortetracycline were 
ambiguous and inconclusive, with a 4% annual increase at MIC value 1 µg/ml but a 5-
7% annual decrease at MIC values 4 µg/ml as compared to lower MIC values.   
Haemophilus parasuis 
 
There were no breakpoints available for any of the antimicrobials for A. suis and detailed 
MIC distributions are presented in table 4-5. There was no significant change in the odds 
of having different MIC values for chlortetracycline, tiamulin, trimethoprim-
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sulphamethoxazole and spectinomycin. However, there was a consistent annual increase 
of 9-20% in the odds of having higher MIC levels for ampicillin (0.5 µg/ml), florfenicol 
(0.5 µg/ml), gentamicin (2 µg/ml) and penicillin (0.25 µg/ml) as compared to lower 
MIC values (p<0.01) (figures 4-1e, f, g, h). This annual increase was even higher for 
ceftiofur (0.5 µg/ml), enrofloxacin (0.25 µg/ml), and tulathromycin (2 µg/ml) MIC 
values as compared to lower MIC values, ranging between 23-34% (p<0.01) (figures 4-1 
i, j, k). There was a 12% annual decrease in odds of being at high MIC values for 
sulphadimethoxine (>256 µg/ml) (p<0.01). The annual change in odds of having different 
MIC values were inconclusive for oxytetracycline, with a statistically significant decrease 
in annual odds at one MIC level but non-significant changes in odds for other MIC 
values. 
Impact of the use of different breakpoints on interpretation of AMR data in A. suis and H. 
parasuis  
 
Overall, the effect of using different breakpoints for interpretation of AMR data on the 
prevalence of resistance was evident in both bacterial species for several antimicrobials 
assessed (tables 4-6 and 4-7). Breakpoints used in the estimations ranged from 1-3 
dilution levels for the different antimicrobial-bacterial species combinations. The effect 
of using different breakpoints on the estimated annual changes was often negligible and 
confidence intervals of estimates for the same bacteria-antimicrobial combination but 
using different breakpoints were overlapping. However, there were differences in 
agreement between AMR prevalence estimates calculated using different breakpoints 
(table 4-7). For A. suis, PABAK coefficients were good, fair and poor for 5, 1 and 2 out 
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of 8 pairs of breakpoints compared. For H. parasuis, PABAK coefficents were good and 
fair for 4 pairs of breakpoints each.  
Discussion 
 
The SRDC causes huge economic losses and increased mortality in swine herds 
worldwide. Antimicrobials are one of the main tools for control of SRDC, but there is 
limited available information on the prevalence of AMR in these bacteria in comparison 
with other zoonotic pathogens such as Salmonella or Campylobacter (NARMS), even 
though this information could help to guide therapy and detect changes over time. In this 
study, we estimated the prevalence of AMR against a panel of 13 antimicrobials and the 
changes in the levels of resistance over a decade in key bacterial pathogens involved in 
SRDC in the U.S. using data collected at the UMN-VDL, a NARMS laboratory that 
processes a large number of swine samples in the country. 
 For S. suis, resistance levels determined in swine isolates from Europe for 
ampicillin, ceftiofur, enrofloxacin and florfenicol resistance were similar to the results 
reported here (<3%), whereas higher levels, compared to Europe, were observed for 
trimethoprim-sulphamethoxazole (3-12% compared with 2% here).116,476–480 Reports on 
penicillin resistance levels in Europe are much more heterogeneous (ranging from <2% to 
>21%)477,478,480 but in some cases were in agreement with values described here 
(7%).476,479 With a few exceptions, European studies also reported tetracycline resistance 
levels above 80% in S. suis isolates.116,476–480 For those antimicrobials with no available 
breakpoints (gentamicin, spectinomycin, tiamulin and tulathromycin) the estimated 
MIC50 and MIC90 values were within one dilution level of those reported previously in 
Europe,116,476,478–480 with the only exception of a lower MIC90 value (16 µg/ml) for 
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spectinomycin478 and higher MIC50 (32 µg/ml) and MIC90 (128 µg/ml) values for 
tiamulin477 compared to the findings of this study.  
Outside Europe reports of the prevalence of AMR in S. suis are highly variable. 
Prevalence levels similar to those reported here were also reported for ampicillin, 
enrofloxacin, penicillin, tetracycline and trimethoprim-sulphamethoxazole resistance in 
Australian S. suis isolates, while higher levels of florfenicol resistance were observed 
(15%) compared to our results.481 In stark contrast, Chinese S. suis were found to be 
highly resistant to clindamycin (98%), ceftiofur (56%) and penicillin (75%).482  
AMR prevalence to ceftiofur, enrofloxacin, florfenicol, tulathromycin and 
trimethoprim-sulphamethoxazole and MIC50 and MIC90 values for tiamulin and 
spectinomycin  in European and Australian P. multocida isolates were similar to values 
found here.116,483 However, both Dayao et al. (2014) and El Garch et al. (2016) found that 
20-28% of the P. multocida isolates were tetracycline resistant, whereas 40-60% of P. 
multocida isolates in this study were chlortetracycline and/or oxytetracycline 
resistant.116,483 In contrast, the prevalence of resistance to antimicrobials (spectinomycin, 
chlortetracycline, trimethoprim-sulphamethoxazole), MIC50, and MIC90 values 
(gentamicin) reported from clinical swine isolates in China was higher with the exception 
of ceftiofur and florfenicol resistance (Tang et al., 2009).484 Similarly, in isolates from 
diseased pigs in Taiwan, prevalence of enrofloxacin (61%), florfenicol (92%), and 
tiamulin (MIC50 – 128 µg/ml, MIC90- >128 µg/ml) resistance was comparatively 
higher.485   
 In absence of clinical breakpoints and epidemiological cut-offs, MIC distributions 
are an alternative source of information on AMR levels.486 For H. parasuis, MIC50 and 
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MIC90 values for ampicillin, ceftiofur, florfenicol, gentamicin, penicillin, tetracycline, 
tulathromycin and tiamulin reported here were at least three dilution levels higher 
compared with values reported in European studies.116,487 Dayao et al. (2014) estimated 
MIC90 values similar (florfenicol, oxytetracycline) or 4-7 double dilutions lower 
(ampicillin, ceftiofur, penicillin) in Australian H. parasuis isolates as compared to this 
study.488 In contrast, MIC90 values estimated by Zhao et al. (2018) in Chinese H. parasuis 
isolates for ceftiofur, enrofloxacin, florfenicol, gentamicin and tetracycline were 2-7 
dilution steps higher as compared to isolates in this study.489 To the best of our 
knowledge, this is the first study to publish MIC distributions for A. suis and hence, 
results comparison to earlier studies was not possible.  
 Significant changes in the MIC distributions of some bacterial-antimicrobial 
combinations over the years were observed in this study. Notable changes included 
increases >10% in odds of being at higher MIC values for gentamicin and tiamulin (S. 
suis) and 7 antimicrobials in H. parasuis isolates; However, decreases >10% in the odds 
of being at higher MIC values for 5 antimicrobials in A. suis and sulphadimethoxine in H. 
parasuis isolates were also reported.  Nevertheless, for bacterial-antimicrobial 
combinations for which breakpoints were available, the prevalence of resistance never 
exceeded 10%, even though some trends were statistically significant (tables S4-1, S4-2, 
S4-3 and S4-4). Similarly, El Garch et al. (2016) reported no change in AMR in 
European S. suis and P. multocida isolates, except for a significant increase in ceftiofur 
resistance and a non-significant increase to tetracycline resistance in S. suis. A drastic 
increase in resistance to spectinomycin and tiamulin and non-significant changes in 
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resistance to other antimicrobials in S. suis isolates was also reported by Hernandez-
Garcia et al. (2016).476  
The interpretation of AMR data is severely hindered due to lack of host-bacteria-
antimicrobial specific clinical breakpoints.116 Moreover, we have shown here that the use 
of different breakpoints may have a significant impact on the estimates of prevalence of 
resistance and thus, breakpoints from related bacteria should be used cautiously for 
interpretive purposes. Cusack et al. (2018) re-analyzed 20 AMR studies using CLSI and 
EUCAST breakpoints for Enterobacteriaceae and observed significant discrepancies in 
prevalence estimates in 19 of them.490 Although we estimated that the odds of being at 
higher MIC levels for several antimicrobials were changing significantly, the clinical or 
epidemiological interpretation of these results can be contentious due to lack of 
interpretive criteria. Moreover, the methodology of susceptibility testing of H. parasuis 
and A. suis has not been standardized by CLSI or EUCAST.487,491 Hence, there is a clear 
need to establish methodology, epidemiological cut-offs and clinical breakpoints for 
bacteria relevant to animal health to make clinical and epidemiological references.470  
 There are some limitations that should be considered in the context of this study. 
First, information on the serotype or presence of virulence factors was not available for 
any bacteria, and for instance serotype distribution has been associated with AMR in S. 
suis and H. parasuis (Yeh et al., 2016; Yongkiettrakul et al., 2019).485,492  Second, the 
information on antimicrobial use in the farm prior to collection of the analyzed samples 
was not available. Third, the isolates were mostly from Minnesota and might not be 
representative of true prevalence of AMR in these swine pathogens in the whole U.S. 
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However, incorporating geographical information in statistical models did not lead to 
significant changes in the estimates.  
Conclusions 
 
We described the prevalence and changes of AMR in some key bacterial pathogens of 
great importance to swine medicine. Results described here will help in surveillance of 
AMR in these critical swine pathogens and aid in informed decision-making regarding 
antimicrobial use in swine medicine. Future research work should focus on continuing 
and strengthening AMR surveillance in these pathogens, as well as establishing 
standardized methods to test AMR in A. suis and H. parasuis and epidemiological cut-
offs and clinical breakpoints for specific bacterial species so that results can be 
harmonized globally. Additionally, genomic characterization and correlating MIC values 
with presence/absence of AMR genes in these pathogens can aid in allowing 
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Ampicillin  2 2 NA NA 
Ceftiofur  8 8 NA NA 
Chlortetracycline  2 2 NA NA 
Enrofloxacin  2 1 NA NA 
Florfenicol  8 8 NA NA 
Gentamicin  NA 16 NA NA 
Oxytetracycline  2 2 NA NA 
Penicillin  1 1 NA NA 
Spectinomycin  NA >64 NA NA 
Sulphadimethoxine  NA NA NA NA 
Tiamulin  NA NA NA NA 
Trimethoprim-
Sulphamethoxazole  
4 NA NA NA 
Tulathromycin  NA 64 NA NA 







Table 4-2. MIC distribution frequencies of Streptococcus suis isolates collected at UMN-VDL from 2006-2016.  





98.0 1.0 0.3 0.2 0.2 0.1 0.2 
     
0.6 ≤0.25 ≤0.25 
Ceftiofur (7025)   93.7 3.2 1.4 0.7 0.5 0.5 
     
1.0 ≤0.5 ≤0.5 
Chlortetracycline 
(7011) 
   
1.0 0.7 2.0 13.4 78.8 
     
94.9 >8 >8 
Enrofloxacin 
(6377) 
6.3 35.3 51.0 5.9 0.8 0.7 
       
1.5 0.5 0.5 
Florfenicol (7002) 
 
0.9 3.4 19.9 68.6 6.2 0.7 0.3 
     





8.0 27.6 46.4 15.0 1.5 1.5 
    




2.9 1.7 0.7 1.1 4.3 89.3 
     
95.4 >8 >8 
Penicillin (7025) 86.5 3.3 3.2 2.6 2.8 0.9 0.4 0.3 
     
7.0 ≤0.12 0.5 
Spectinomycin 
(7025) 
      
6.7 51.3 29.0 2.8 10.2 
  
- 16 >64 
Sulphadimethoxine 
(7016) 
           






23.3 42.3 15.5 2.7 1.6 2.9 4.6 7.1 
   




    
98.0 2.0 





   
7.6 13.4 7.5 1.1 0.7 1.5 2.8 65.4 
  
- >64 >64 
Shaded areas indicate concentrations not tested. Red lines demarcate resistant and not-resistant isolates based on swine-specific breakpoints (CLSI, 2018) except 
trimethoprim-sulphamethoxazole (human-specific breakpoints). *- number of isolates tested for susceptibility to this antimicrobial. 
 
 
Table 4-3. MIC distribution frequencies of Pasteurella multocida isolates collected at UMN-VDL from 2006-2016. 





85.0 8.5 2.4 1.2 0.6 0.4 0.4 1.6 
    
4.2 ≤0.25 0.5 
Ceftiofur (8670) 
  
96.9 1.3 0.4 0.3 0.4 0.7 
     




33.2 26.4 23.5 12.0 3.4 1.5 
     





93.9 3.2 2.1 0.4 0.2 0.2 
       
0.8 ≤0.12 ≤0.12 
Florfenicol (8670) 
 
21.9 59.6 11.3 5.5 0.6 0.3 0.8 
     
1.1 0.5 1 
Gentamicin (8671) 
   
36.8 48.5 11.3 1.6 0.9 0.9 
    




24.0 13.8 26.3 8.9 2.7 24.3 
     
62.2 2 >8 
Penicillin (8671) 77.6 14.7 2.8 1.4 0.9 0.4 0.5 1.7 
     
4.8 ≤0.12 0.25 
Spectinomycin 
(8671) 
      
15.1 32.7 43.3 6.7 2.1 
  
2.1 32 32 
Sulphadimethoxine 
(8665) 
           
28.5 71.5 - 
  
Tiamulin (8666) 
     
2.2 8.7 31.7 43.3 14.1 
   




    
95.9 4.1 





   
55.3 25.6 12.1 3.6 0.8 0.7 0.7 1.3 
  
2.0 ≤1 4 
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Shaded areas indicate concentrations not tested. Red lines demarcate resistant and not-resistant isolates based on swine-specific breakpoints (CLSI, 2018) except 
spectinomycin (cattle-specific breakpoints). *- number of isolates tested for susceptibility to this antimicrobial. 
 
 
Table 4-4. MIC distribution frequencies of Actinobacillus suis isolates collected at UMN-VDL from 2006-2016. 
Antimicrobial (n)* 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 MIC50 MIC90 
Ampicillin (2862) 
 
83.5 9.3 1.5 0.7 0.6 0.7 0.9 2.9 




93.7 2.7 1.5 1.2 0.5 0.1 0.2 





37.8 30.1 8.8 13.6 7.6 2.0 




94.4 3.0 1.6 0.5 0.3 0.2 




8.5 72.1 15.3 3.2 0.3 0.1 0.5 
     
0.5 1 
Gentamicin (2866) 
   
61.2 33.1 3.7 0.7 0.6 0.6 





49.1 20.1 0.9 0.5 1.7 27.7 
     
1 >8 
Penicillin (2866) 6.1 10.7 52.6 23.0 2.5 0.3 0.5 4.3 






      










0.2 0.1 0.2 1.2 42.1 50.6 4.6 0.8 





    
98.6 1.4 
         
Tulathromycin 
(2432) 
   
20.8 61.4 11.3 2.6 0.5 0.3 0.7 2.4 
  
2 4 
Shaded areas indicate concentrations not tested.  









Table 4-5. MIC distribution frequencies of Haemophilus parasuis isolates collected at UMN-VDL from 2010-2016. 
Antimicrobial (n)* 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 512 MIC50 MIC90 
Ampicillin (1658) 
 
46.8 9.8 11.3 10.2 7.4 2.1 0.9 11.5 




82.8 5.6 3.6 1.3 0.7 0.4 5.7 





82.1 9.2 6.6 1.2 0.6 0.2 




94.8 2.8 1.6 0.4 0.2 0.3 




58.5 34.4 5.5 1.3 0.1 0.1 0.1 
     
≤0.25 0.5 
Gentamicin (1658) 
   
22.9 24.0 33.4 15.9 3.0 0.8 





53.3 15.7 13.0 5.1 4.5 8.4 
     
≤0.5 8 
Penicillin (1658) 38.7 17.4 14.8 10.8 5.9 1.1 1.1 10.1 




      










7.7 12.2 21.5 27.7 22.0 7.5 1.0 0.5 







    
86.1 13.9 
         
Tulathromycin 
(1658) 
   
21.5 16.9 20.8 24.0 9.3 4.2 1.6 1.8 
  
4 16 
Shaded areas indicate concentrations not tested.  





Table 4-6. Impact of using different breakpoints on estimation of prevalence of AMR and 
changes in AMR over time. 
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(0.95
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*- Time associated odds ratio obtained by using year as a continuous independent variable 
in binary logistic regression models using these breakpoints. 
a- CLSI (2018) breakpoints for Actinobacillus pleuropneumoniae471 
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b- Zhou et al. (2010)493 
c- Dayao et al. (2014)488 
d- de la Fuente et al. (2007)494 
e- Kucerova et al. (2011)495 
f- El Garch et al. (2016)116 
g- CLSI (2018) breakpoints for Histophilus somni471 
 
Table 4-7. Agreement between prevalence estimates of antimicrobial resistances after 
using different breakpoints based on unbiased Kappa and prevalence-associated bias-















Ampicillin (2 vs 4) 0.94 0.99 0.75 0.80 
Ampicillin (2 vs 8) 0.87 0.98 0.55 0.66 
Chlortetracycline (2 vs 
8) 
0.61 0.63 0.16 0.84 
Chlortetracycline (2 vs 
16) 
0.08 0.4 0.04 0.83 
Enrofloxacin (1 vs 2) 0.66 0.98 0.76 0.99 
150 
 
Gentamicin (8 vs 16) 0.78 0.99 0.28 0.68 
Penicillin (1vs 4) 0.21 0.48 0.51 0.67 
Tulathromycin (16 vs 
64) 
0.90 0.99 0.29 0.73 









































Figure 4-1. Changes in MIC distributions over years for select bacterial-antimicrobial 
combinations. 
 





















































































































































































































































































































































































































































































































































































































- 1.06 (0.97-1.16) 0.23 
Ceftiofur Breakpoint 
available 
- 1.19 (1.10-1.29) <0.01 
Chlortetracycline Breakpoint 
available 
- 1.0 (0.97-1.03) 0.99 
Enrofloxacin Breakpoint 
available 
- 0.96 (0.90-1.02) 0.19 
Florfenicol  Breakpoint 
available 
- 0.89 (0.82-0.96) <0.01 
Oxytetracycline Breakpoint 
available 
- 1.01 (0.97-1.04) 0.74 
Penicillin Breakpoint 
available 






≤ 256 vs > 
256 






- 0.98 (0.93-1.04) 0.5 
Gentamicin No ≤ 2 vs ≥ 4 1.16 (1.15-1.18) <0.01 
  
≤ 4 vs ≥ 8 1.10 (1.08-1.13) <0.01 
Spectinomycin No ≤ 8 vs ≥ 16 1.05 (1.02-1.08) <0.01 
  
≤ 16 vs ≥ 32 0.93 (0.92-0.94) <0.01 
  




≤ 64 vs ≥ 128 1.03 (1.0-1.05) <0.01 
Tiamulin No ≤ 0.5 vs ≥ 1 1.01 (0.89-1.15) 0.25 
  
≤1 vs ≥ 2 0.90 (0.89-0.91) <0.01 
  
≤ 4 vs ≥ 8 1.05 (1.03-1.07) <0.01 
Tulathromycin No ≤1 vs ≥ 2 1.07 (1.03-1.12) <0.01 
  
≤ 2 vs ≥ 4 1.01 (0.99-1.04) 0.37 
  
≤ 4 vs ≥ 8 1.0 (0.98-1.03) 0.83 
  


































- 0.98 (0.90-1.06) 0.56 
Florfenicol  Breakpoint 
available 
- 1.06 (0.99-1.13) 0.09 
Gentamicin Breakpoint 
available 
- 1.02 (0.97-1.07) 0.49 
Oxytetracycline Breakpoint 
available 










- 0.90 (0.85-0.94) <0.0
1 






- ≤ 2 vs > 2 0.97 (0.94-1.01) 0.06 
Tulathromycin Breakpoint 
available 
- 1.0 (0.95-1.06) 0.9 
Tiamulin No ≤ 4 vs ≥ 8 0.92 (0.88-0.96) <0.0
1 
  
≤ 8 vs ≥ 16 0.96 (0.94-0.97) <0.0
1 
  
≤ 16 vs ≥ 32 0.98 (0.96-0.99) <0.0
1 
  























Ampicillin Yes - 0.96 (0.93-0.99) <0.01 
Ceftiofur No ≤ 0.25 vs ≥ 
0.5 
0.82 (0.77-0.87) <0.01 
  
≤1 vs ≥ 2 0.71 (0.64-0.79) <0.01 
Chlortetracycline No ≤ 0.5 vs ≥ 1 1.04 (1.02-1.07) <0.01 
  
≤ 2 vs ≥ 4 0.93 (0.90-0.96) <0.01 
  
≤ 4 vs ≥ 8 0.95 (0.91-0.99) <0.01 
Enrofloxacin  Yes - 1.05 (0.99-1.11) 0.05 
Florfenicol No ≤ 0.5 vs ≥ 1 0.92 (0.89-0.95) <0.01 
  
≤1 vs ≥ 2 0.99 (0.94-1.06) 0.87 
Gentamicin Yes - 0.99 (0.96-1.01) 0.24 
Oxytetracycline No ≤ 0.5 vs ≥ 1 0.98 (0.95-1.0) 0.06 
  
≤1 vs ≥ 2 0.90 (0.87-0.92) <0.01 
  
≤8 vs ≥ 16 0.90 (0.87-0.92) <0.01 
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Penicillin No ≤ 0.25 vs ≥ 
0.5 
1.05 (1.10-1.08) <0.01 
  
≤ 0.5 vs ≥ 1 0.97 (0.95-1.0) 0.02 
  
≤1 vs ≥ 2 0.95 (0.91-0.99) <0.01 
  
≤8 vs ≥ 16 0.95 (0.90-1.01) 0.09 
Spectinomycin Yes - 0.83 (0.81-0.86) <0.01 
Tiamulin Yes - 0.85 (0.83-0.87) <0.01 
Tulathromycin No ≤1 vs ≥ 2 0.73 (0.70-0.76) <0.01 
  
≤ 2 vs ≥ 4 0.82 (0.78-0.85) <0.01 
  
≤ 4 vs ≥ 8 0.89 (0.83-0.94) <0.01 
  
≤ 32 vs ≥ 64 0.93 (0.86-1.01) 0.09 
Sulphadimethoxine - ≤ 256 vs > 
256 
0.82 (0.80-0.85) <0.01 
Trimethoprim-
Sulphamethoxazole 
















values vs higher 






Ampicillin Yes - 1.20 (1.14-
1.26) 
<0.01 
Ceftiofur Yes - 1.25 (1.17-
1.33) 
<0.01 
Chlortetracyline Yes - 1.01 (0.94-
1.08) 
0.84 
Enrofloxacin Yes - 1.34 (1.20-
1.49) 
<0.01 
Florfenicol Yes - 1.09 (1.04-
1.15) 
<0.01 
Gentamicin Yes - 1.14 (1.09-
1.20) 
<0.01 










≤ 4 vs ≥ 8 0.99 (0.92-
1.07) 
0.88 
Penicillin Yes - 1.12 (1.07-
1.18) 
<0.01 
Spectinomycin Yes - 1.03 (0.97-
1.10) 
0.3 




























CHAPTER-5 Genetic determinants of extended spectrum cephalosporin 




Antimicrobial resistance has emerged as an issue of great concern in both human and 
veterinary medicine. Food animals are considered as potential reservoirs of antimicrobial 
resistant, zoonotic pathogens such as Escherichia coli, although the extent of spread of 
resistant bacteria via food chain is still debatable.2 Antimicrobials that have critical 
importance in human medicine such as cephalosporins and fluoroquinolones are still used 
routinely in many parts of the world to treat diseased food animals, including swine in 
USA.447,496 Furthermore, certain genetic mechanisms responsible for resistance to 
antimicrobials approved for use in animals (such as ceftiofur and enrofloxacin) and those 
used in human medicine (such as cefoxitin and ciprofloxacin) are the same.497,498 It is 
therefore important to monitor the circulation of genes responsible for resistance to 
critically important/key antimicrobials, such as 3rd generation or higher cephalosporins 
and fluoroquinolones, in bacteria present in humans and animals to develop better source 
attribution models and targeted interventions in both humans and veterinary medicine.499  
 Resistance to extended-spectrum cephalosporins is mediated by extended 
spectrum beta- 
lactamases (ESBLs), (commonly encoded by the blaTEM, SHV, CTX-M families of genes) 
and plasmidic AmpC (commonly encoded by the blaCMY family of genes).
343 These genes 
may be inserted on bacterial chromosomes but are usually present on plasmids which 
have the potential to disseminate horizontally to other bacterial strains. blaCTX-M genes are 
reported as the most prevalent ESBL encoders worldwide in humans and animals.103 
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However, ESBL-encoding genes were absent and blaCMY genes were primary responsible 
for extended spectrum cephalosporin resistance in bacteria of food animal origin in North 
America until the late 2000’s.500 However, recent reports have also suggested the 
emergence of ESBL genes in bacteria of food animal origin in USA over the last 
decade.501 
Resistance to fluoroquinolones is mainly mediated by multiple chromosomal 
mutations in certain genes (gyrA, gyrB, parE and parC). Additionally, plasmid mediated 
quinolone resistance genes (such as qnr) and upregulation of efflux pumps confer 
variable levels of resistance to this antimicrobial family.13 An increase in fluoroquinolone 
resistance was recently reported in Salmonella spp. isolates from diseased pigs in 
Minnesota between 2006 to 2015.447 qnr genes encoded in plasmids were also found in 
Salmonella spp. isolates collected from retail pork, cecal samples from healthy pigs and 
clinical samples from diseased pigs in USA.454,502,503  
Other antimicrobials which are critically important in human medicine include 
carbapenems, colistin and fosfomycin. Carbapenems are considered as last resort 
antimicrobials for severe infections in humans and are not used in food animals 
worldwide.106 The genetic determinants for carbapenem resistance belong to bla family 
of genes that also confer resistance to cephalosporins and penicillins.504 Colistin has been 
used in food animal medicine but has been recently reintroduced in human medicine as a 
“last resort” antimicrobial to treat multidrug resistant infections.110 Colistin resistance has 
also gained considerable limelight in recent years due to the emergence of plasmid 
mediated mobile resistance genes (mcr genes) which have the potential to disseminate 
horizontally,14 and the presence of mcr genes on plasmids also carrying ESBL-encoding 
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or carbapenem resistance genes.505,506 Fosfomycin has been used for treating 
uncomplicated urinary tract infections in humans but its use is being considered in more 
complicated infections due to its activity against multidrug resistant pathogens.507 
 Although increasing information on the prevalence of phenotypic resistance in 
bacteria (including E. coli) of animal origin is generated thanks to national AMR 
monitoring programs, there is limited information on the genetic backbone mediating 
these resistance phenotypes. This may be of particular importance in the case of critically 
important antimicrobials such as fluoroquinolones, cephalosporins or carbapenems. The 
objective of this study was to characterize the genomic basis of fluoroquinolone and 
extended spectrum cephalosporin resistance in phenotypically resistant E. coli isolates 
collected from diseased pigs in USA between 2014-15 using short read whole genome 
sequencing (WGS). Both short and long read sequencing were used to characterize 
plasmids carrying ESBL, pAmpC and qnr genes which have not been previously reported 
in swine E. coli isolates in USA. The presence of mcr-9 and fosfomycin resistance genes 
(fosA7) in swine E. coli isolates was also identified for the first time in USA. 
 
Materials and methods 
 
A total of 212 E. coli isolates from diseased pigs collected at the University of Minnesota 
Veterinary Diagnostic Laboratory (UMN-VDL) between 2014-2015 were included in this 
study. These isolates were selected on the basis of results of broth microdilution test 
routinely performed at the laboratory using CLSI guidelines (add citation to CLSI). Out 
of these 212 isolates, 93 had enrofloxacin MIC values 1 g/ml and 106 had ceftiofur 
MIC values 8 g/ml. Eighteen isolates had enrofloxacin MIC 1 g/ml and ceftiofur 
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MIC 8 g/ml and 45 isolates had MIC values <1 g/ml for enrofloxacin and <8 g/ml 
for ceftiofur. 
 These isolates were first subjected to short read sequencing using Illumina HiSeq 
2500 (2 x 125bp). After initial quality control, draft genomes from these reads were 
assembled de-novo using Spades (version 3.13.0).508 Draft genomes were uploaded to the 
Center for Genomic Epidemiology (CGE) webserver to identify multilocus sequence type 
(MLST),509 acquired resistance genes (Resfinder),510 plasmid sequence type (pMLST)511 
and plasmid replicon types (Plasmid Finder).511 Chromosomal mutations in quinolone 
resistance determining regions (QRDRs) were identified by downloading sequences of 
gyrA, gyrB, parC and parE from reference E. coli k-12 genome (Genbank accession 
number-U00096) and performing nucleotide BLAST against the draft genomes locally 
(version 2.9.0, maximum hits-50, E-value threshold-10). 
 Core genomes of these 212 isolates were identified by first annotating draft 
genomes using PROKKA (version 1.13)512 followed by core genome extraction using 
ROARY (version 3.11.2).513 parSNPs program was used to identify high quality single 
nucleotide polymorphisms in these core genomes (version 1.0).514 Maximum likelihood 
tree was built using general time-reversible with gamma substitution model using RaxML 
(version 8.0).515 Support for nodes on trees was assessed using 5000 bootstrap replicates 
and visualization was done using iTOL (version 4.0).516  
 Additionally, long read sequencing was performed on a subset of isolates that 
were identified as carrying ESBL genes (blaSHV-12, blaCTX-M) in the analysis above using 
PacBio RSII technology (need to define the sequencer and chemistry used, and details 
about the data acquisition). Unicycler (version 0.4.7)517 was used to perform de-novo 
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hybrid assemblies of these isolates using both long and short reads and assemblies were 
visualized using Bandage (version 0.8.1).517 These complete genomes (here on referred to 
as “assembled plasmids”) were uploaded to ISSaga webserver518 for identification of 
insertion sequences and to the CGE webserver to perform analyses as mentioned above. 
These assembled plasmids were also blasted against a database of reference plasmids 
available at PLSDB webserver519 and at NCBI blastn to identify previously described 
plasmids closely related to the plasmids assembled in this study. Plasmids with query 
coverage of >80% and nucleotide identity >90% were considered to be similar to 
assembled isolates in our study. BRIG (version 0.95)520 was used to visualize the 
comparisons of identified closely related plasmids genomes with the assembled plasmids.  
 Putative plasmids were identified by mapping raw reads from short read 
sequences to the assembled plasmids and complete assemblies of plasmids carrying 
blaCMY-2 and qnr genes published recently (Elnekave et al., 2019)




Genetic mechanisms conferring fluoroquinolone and extended spectrum cephalosporin 
resistance  
Out of 106 isolates with ceftiofur MIC values 8 g/ml, 89 (84%) carried blaCMY-2 genes 
(table 5-1). These genes were not present in rest of the 106 isolates with ceftiofur MIC 
values <8 g/ml.  The isolates carrying this gene belonged to 25 different ST types. ST12 
(n=21) and ST101 (n=10) were the dominant ST types (clades 3 and 4, figure 5-1). 
Twenty of the ST12 isolates were potentially clonal and varied only by 9-32 single 
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nucleotide polymorphisms (SNPs). However, the isolates in ST10 and ST101 varied by 
7-4185 and 8-1367 SNPs, respectively. 
 There were 24 isolates belonging to 13 different ST types which carried blaSHV-12 
and blaCTX-M genes, of which 21 were present in isolates with a ceftiofur MIC  8 g/ml 
(table 5-1). The only bla gene found in isolates with ceftiofur MICs <8 g/ml was blaSHV-
12.  
 The patterns of genetic determinants of fluoroquinolone resistance in 93 isolates 
with enrofloxacin MIC values  1 g/ml is presented in table 5-2. These 93 isolates with 
enrofloxacin MIC values 1 g/ml belonged to 27 different ST types. The dominant ST 
types were ST100 (n=37) and ST744 (n=17) (table 5-2). Thirty-six of these ST100 
isolates varied by less than 20 SNPs, indicating potential clonality of these isolates (part 
of CC165, clade-1, figure 5-1). These ST100 isolates were collected from 6 different 
states in USA. In contrast, ST744 isolates varied by 8-606 SNPs (clade-2, figure 5-1).  
 Across all the 212 isolates under study, there were 6 different types of PMQR 
genes in 24 isolates spread across 7 states (table 5-3). Only 17 of these 24 isolates had 
enrofloxacin MIC  1 g/ml (table 5-3). The 24 isolates belonged to 16 different ST 
types (table 5-3). Enrofloxacin MIC values for isolates with a single PMQR, two PMQRs 
and a PMQR with chromosomal mutation (gyrA- S83L, D87G or parE- D476A) ranged 
between 0.5-1.0 g/ml, with the exception of two isolates that carried only qnrB19 but 
had enrofloxacin MIC values of 2 g/ml.   
Description of assembled plasmids carrying PMQRs and ESBLs   
 
We assembled complete plasmids using both long and short reads from eight isolates 
carrying blaCTX-M genes (table 5-4). These genes were present on IncFII and IncHI2 
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plasmids with size ranges of 69-240 kbp. blaCTX-M genes were present in regions flanked 
by IS26, ISEcp1, IS5, IS6 and Tn3 family transposases, which were often truncated (table 
5-4). In one isolate, blaCTX-M-15 was present on the E. coli chromosome and the gene was 
flanked by transposases similar to those surrounding blaCTX-M-15 in the IncF plasmids. 
Plasmids with blaCTX-M-14 or blaCTX-M-27 carried only these or one other AMR gene 
whereas the plasmids carrying blaCTX-M-15 and blaCTX-M-55 genes carried at least two more 
AMR genes.  
The two blaSHV-12 genes were found on large assembled plasmids (approx. 
300kbp), which were of IncHI2 type and carried genes for resistance to fluoroquinolones 
(qnrB2), aminoglycoside, sulphonamide, trimethoprim, tetracycline, penicillin and 
macrolide (Table 3). blaSHV-12 genes were present in a region flanked by intact IS6 
transposases. One of these plasmids (p39SHV) also carried a mcr-9 gene, which was 
present in a region surrounded by intact IS5 and IS6 transposases (table 5-4).  
In addition to these ESBL-encoding plasmids, we identified and assembled a 59 
kbp IncN plasmid carrying qnrB77 gene using hybrid assemblies based on long and short 
reads (table 5-4). This plasmid was present in a ST4981 isolate which also carried an 
ESBL-encoding gene (blaCTX-M-15) chromosomally. This plasmid also carried genes 
which confer resistance to trimethoprim, sulphonamides and aminoglycosides present on 
a class I integron. qnrB77 gene was flanked by a complete and a truncated transposase of 
IS91 family of insertion sequences (table 5-4).  
 On comparison of these assembled plasmids with the PLDSB database using 
nucleotide BLAST, we were able to identify previously described plasmids with a high 
similarity (>80% coverage, and >98% nucleotide identity). In brief, the plasmids carrying 
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ESBL encoding genes assembled in this study were similar to plasmids harbored on 
various Enterobactericaceae and collected from various sources (animals, humans, 
environment) across different continents and shared the same molecular context around 
genes of interest (qnr, bla). In contrast, we were not able to identify a previously 
described plasmid highly similar (>80% coverage) to blaCTX-M-15 carrying IncFII 
(pMLST- F48:A1:B49) plasmids and qnrB15 carrying IncN plasmid found in this study. 
Description of putative plasmids carrying PMQRs and ESBLs  
In 75 of the 89 blaCMY-2-carrying isolates, putative plasmids alignments were 
obtained by mapping the raw reads to an IncA/C2 plasmid (accession number- 
MK191854.1; mean coverage- 74.3%, percent identity- >99%) and an IncI1 plasmid 
(Accession number- MK191846.1; mean coverage-92%, percent identity- >98%) (Table 
5-5). These plasmids were recently described in Salmonella enterica isolates collected 
from diseased swine at UMN-VDL and reaffirm that these are the predominant plasmids 
disseminating extended spectrum cephalosporin resistance in bacteria of family 
Enterobacteriaceae in swine in USA.  
By aligning raw reads with reference plasmids (published by Elnekave et al., 
2019), putative plasmid alignments were identified for isolates carrying qnrB19, qnrS2 
and qnrS1 (table 5-5). Putative plasmids carrying qnrB19 and qnrS2 ranged between 
2757-3126 bp and were classified as ColRNAI-type plasmids encoding only a few 
proteins. Two isolates carrying qnrS2 also aligned with IncQ type plasmids of nearly 
7500bp length described recently by Elnekave et al. (2019). Putative plasmids carrying 
qnrS1 genes were assembled by mapping raw reads to a reference plasmid (Accession 
number- MK356561.1). These putative plasmids were nearly 42kbp in size, belonged to 
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IncN family of plasmids, had a coverage of 72% and an identity of more than 99% as 
compared to the reference plasmid (table 5-5).  
There were 36 isolates which carried either ESBL-encoding or ampC genes and 
PMQR or multiple mutations in QRDRs. There were four isolates which had a single 
mutation in QRDRs and also carried either ESBL or pAmpC genes. Five of the isolates 
carried a blaCMY-2 gene and either blaCTX-M-27, blaCTX-M-55 or blaSHV-12 gene.  
Genetic mechanisms of other critical antimicrobials 
No carbapenem resistance genes were present in these isolates. mcr-9 gene was present in 
6 isolates belonging to 5 different ST types. These isolates carried mcr-9 gene and either 
an ampC, an ESBL or a PMQR gene. Descriptions of these isolates are presented in table 
5-6. mcr-9 was also present on one of the ESBL plasmids (p39SHV) assembled in this 
study (table 5-6).  
Fosfomycin resistance gene (fosA7) was present in 7 of the isolates. Five of these 
isolates were of ST847 type and differed by only 11-57 SNPs. One of these isolates also 
carried qnrS2 gene. Two isolates carrying fosA7 belonged to ST75 and also carried 
blaCMY-2 genes. Contigs carrying this gene were extracted and nucletotide BLASTn 
search was conducted. These contigs matched with chromosomal sequences of E. coli in 
6 of these isolates with a query coverage and nucleotide identity of greater than 90%.   
Discussion 
 
Whole genome sequencing (WGS) of enrofloxacin and/or ceftiofur resistant E. coli 
revealed multiple mechanisms conferring resistance to these critical antimicrobials which 
were present on a wide spectrum of ST types recovered from the major swine producing 
states in USA. A combined approach using long and short read WGS technologies 
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reaffirmed the widespread presence of certain genetic determinants that could contribute 
to the spread of AMR, such as plasmids carrying blaCMY-2, which have established in 
Salmonella and E. coli isolates circulating in food animal production in the past.500 We 
also assembled plasmids which have not been described previously in swine or other food 
animals and retail meat in USA such as those carrying ESBL encoding genes and 
compared them to previously described plasmids which were isolated in other countries, 
indicating that these plasmids carrying ESBL encoding genes were part of a pandemic 
spread of these plasmids. 
Nearly 84% of the ceftiofur resistant isolates (MIC 8 g/ml) carried a blaCMY-2 
gene, which is consistent with findings in ceftiofur-resistant Salmonella isolates from 
diseased pigs collected during same study period.502 However, 24 E. coli isolates in this 
study (including 3 with ceftiofur MICs<8 g/ml) carried a blaCTX-M or blaSHV-12 gene. In 
comparison to ceftiofur resistant Salmonella spp. isolated from diseased pigs in USA,502 
we reported a much higher prevalence (18%) of blaCTX-M in our isolates. Nevertheless, 
according to our findings the distribution of blaCTX-M genes is more limited compared 
with reports in ESBL- E. coli isolates retrieved from swine in European and Asian 
countries (range-33 to 100%) (Chapter 2). ESBL-encoding genes are the predominant 
genes responsible for extended spectrum cephalosporin resistance globally in food 
animals (Bevan et al., 2016). However, until the late 2000’s these genes were not found 
in food animal isolates collected in North America.522 In a study on E. coli isolates 
collected from diseased pigs at UMN-VDL in 2008, all ceftiofur resistant isolates carried 
blaCMY-2 genes
58; whereas blaCTX-M carrying E. coli in finishing pigs in USA were first 
identified in 2011.367 There are a few more recent studies that have reported the sporadic 
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occurrence of blaCTX-M genes in Enterobacteriaceae isolates of swine origin (including 
pork) in USA.523,524  
Similar to ESBLs, presence of PMQRs (qnr, aac) in food animal isolates in USA 
has not been reported until recently.450,454,502,525 PMQR genes identified in this study such 
as qnrB and qnrS have also been reported from E. coli and Salmonella isolates of swine 
origin in Asia, Australia and Europe. There has also been an increase in PMQR genes is 
Salmonella isolates collected from diseased humans in USA and animal sources might 
contribute to this surge.525 The presence of PMQR genes without presence of 
chromosomal mutations in QRDR was able to elevate MIC values to intermediate levels 
(1 g/ml) but not to higher MIC levels. This is consistent with the previous reports that 
PMQRs like qnrB and qnrS confers lower level resistance to quinolones by inhibiting 
binding of quinolones to DNA gyrase.526 However, these PMQRs are known to 
supplement resistance caused by other mechanisms such as altered target enzymes (DNA 
gyrase), efflux pump activities and deficiencies in outer membrane porin channels.527 The 
presence of PMQRs in zoonotic bacteria and their clinical impact on both human and 
animal health should be continuously monitored.  
 The presence of a large number of different ST types along with a few isolated 
clones of E. coli carrying PMQRs, ESBLs and chromosomal mutations in QRDRs across 
major swine producing states in USA is indicative of widespread horizontal and clonal 
dissemination of these genetic mechanisms. This pattern of both clonal and horizontal 
transmission is consistent with recent studies in Germany where clones of certain ST 
types (ST167 and ST410) of E. coli were associated with carriage of blaCTX-M-15 while 
overall there were 26 ST types carrying this gene.528,529  
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ESBLs have been associated with pandemic ST131 E. coli in humans.530 
However, in this study only one ST131 isolate was identified, and it was considered 
susceptible to both antimicrobial classes under study. The main swine specific ST type 
with enrofloxacin MIC (1 g/ml) identified in this study was ST100, which is 
associated with porcine enterotoxigenic infections.128 Enrofloxacin has been introduced 
to treat swine enteric infections in USA since 2012447 and the association of ST100 with 
enrofloxacin resistance might be of concern to swine health. Some of the major 
cephalosporin and /or fluoroquinolone resistant ST types (ST744, ST10CC, ST86CC, 
ST23CC, ST58) identified in our panel have been associated with carriage of blaCTX-M in 
multiple animal species, have been implicated in human infections and are considered 
“zoonotic ST types”.531–535 The presence of these resistant ST types in swine may suggest 
a potential risk of spread to other animal species including humans. 
Putative plasmids carrying blaCMY-2, qnrS1, qnrS2, qnrB2 and qnrB19 were 
aligned using complete plasmid assemblies described by Elnekave et al. (2019)502 and we 
refer the readers to this article for further details on the above-mentioned plasmids. To 
the best of my knowledge, this is the first study to describe completely assembled 
plasmids carrying blaCTX-M-14, -15, -27, -55, blaSHV-12 and qnrB15 in E. coli isolates of swine 
origin in USA. However, the close identities between some plasmids in this study and 
those already described in humans and animals globally indicate that the presence of 
ESBL genes in this isolate collection could be a part of the pandemic expansion of 
ESBLs.103 blaCTX-M-15 and blaCTX-M-14 are considered to be predominant ESBL genes in 
humans globally103 and have also been identified in food animals including pigs 
worldwide (Chapter-2). The plasmid carrying blaCTX-M-15 (p1CTX) in our study was 
177 
 
highly similar (98% coverage, >99% nucleotide identity) to the ones identified in human 
E. coli isolates collected in USA between 2009-10,536 (Genbank accession number-
CP009232) which were further described to have the same plasmid backbone as ESBL 
gene carrying plasmids worldwide.536 blaCTX-M-27 carrying plasmids identical to those in 
this study have been previously isolated from humans in USA537 and England538 and sick 
ducks in China539. blaCTX-M-55 carrying plasmids similar to ones in this study have been 
isolated from various human and animal sources in South Korea, China and England 
(unpublished, Genbank accession numbers- KM396298.1, KM396299.1, KM396300.1, 
NZ_CP0309401.1, NZ_CP036178.1, MG014721.1, MK169211.1). blaCTX-M-14 carrying 
plasmids identical to those in this study have been previously isolated from humans in 
Hong Kong and has been characterized as an epidemic plasmid type (pHK01)540 which 
has spread globally to other Asian countries (China, Vietnam, South Korea) and 
European countries (Finland) (unpublished, Genbank accession numbers- NC_013727.1, 
KU932024.1, KU987452.1, NC_013542.1, NZ_CP018973.1). blaSHV-12 carrying plasmids 
similar to ones in this study have been isolated from various human and animal sources in 
USA,541 China542, Taiwan543 and Denmark544. Moreover, these plasmids were isolated 
from different bacterial species such as Salmonella, Klebsiella, Enterobacter, E. coli–
ST131 etc. and had identical genetic contexts around blaCTX-M and blaSHV-12 genes as in 
plasmids assembled in this study. Insertion sequences (IS26, ISEcp9, IS6) that were part 
of the above-mentioned genetic contexts have been demonstrated to be successful in 
transposing ESBL-encoding genes across plasmids and bacterial chromosomes.545   
It has been widely believed that the presence of plasmids in the absence of 
selective pressure imposes a metabolic fitness cost to the bacterial host.546 However, the 
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fitness cost imposed due to plasmid carriage depends on the plasmid-bacterial host 
combination.547–549 There are several plasmid characteristics which help in plasmid 
stability in bacterial hosts. For example, IncF plasmids have a narrow host range and 
carry factors such as addiction systems, post-segregational killing machinery etc. which 
help in maintaining their stability in bacterial hosts without antimicrobial pressure.550 
Similarly, IncHI2 plasmids carry genes which confer resistance to heavy metals, 
mutagenesis induction system etc. which aid in their stability.551 Endemic plasmids 
identical to those found in our study such as pHK01-like plasmids have been 
demonstrated to be conjugative in-vitro.552 Hence, it can be postulated that these plasmids 
might aid in establishment of ESBLs as dominant mechanisms behind extended spectrum 
cephalosporin resistance in swine in USA as has happened globally.  
This is the first report of the presence of mcr-9 and fosA7 in any bacteria from 
food animals in USA. mcr-9 gene was recently described for the first time in a S. 
Typhimurium isolate collected from a human patient in Washington State, USA and was 
able to confer colistin resistance to E. coli isolates cloned with this gene.553 It should be 
noted that colistin has never been used in swine production in USA and the presence of 
mcr-9 gene in the absence of colistin use could be an indicator of the complex 
transmission dynamics of resistant mechanisms across different ecosystems and/or co-
selection of resistant mechanisms due to use of unrelated antimicrobials. We also 
reported the presence of fosA7 gene in E. coli isolates of swine origin in USA. fosA7 gene 
was discovered only recently in S. Heidelberg isolates from poultry in Canada554 but 
never been described in E. coli. Moreover, fosfomycin resistance genes are thought to be 
plasmid mediated in E. coli isolates555 but the contigs carrying these genes in this study 
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matched with chromosomal sequences available in Genbank database. Further analyses 
of isolates carrying mcr-9 and fosA7 is needed  
Several limitations must be considered when interpreting these results. These 
isolates were collected from diseased pigs submitted for diagnostic purposes that might 
therefore have been treated with antimicrobials before submission. An association 
between antimicrobial use and presence of these genes should not be established on the 
basis of these results until further studies are conducted. Also, diseased pigs are removed 
from the food chain and therefore the presence of resistant and potentially zoonotic ST 
types does not imply an immediate risk for public health. Nevertheless, the putative 
plasmids carrying qnr genes found here were identical to those isolated from Salmonella 
spp. collected from retail pork and cecal samples from healthy pigs,454 suggesting they 
may eventually go through the food processing chain. Hence, these isolates might still 
indicate a potential reservoir for human infections and WGS data presented here can aid 
in making better source attribution models in the future.   
Conclusions 
 We were able to identify and describe novel genetic mechanisms of resistance to some 
critical antimicrobial classes important to both human and animal health in swine clinical 
E. coli isolates, some of which had never been described in isolates of animal origin in 
the US. Future studies will focus on assembling finished genomes of isolates carrying 
mcr-9 and fosA7 genes as well as conducting conjugation and fitness experiments on 
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Tables 
Table 5-1. Number and type of ESBL and pAmpC genes and associated ST types in 106 













12 (n=21), 10 (n=12), 101 (n=10), 100 
(n=9), 58 (n=6), 23 (n=4), 410 (n=4), 90 
(n=3), 744 (n=3), 75 (n=2), 69 (n=1), 73 
(n=1), 88 (n=1), 93 (n=1), 127 (n=1), 154 
(n=1), 224 (n=1), 369 (n=1), 761 (n=1), 
977 (n=1), 2025 (n-1), 3057 (n=1), 4373 
(n=1), 6234 (n=1) 
MN, CO, IA, IL, 
KS, MI, MO, 
NE, OH, OK, 
SD, TN, TX, WI 
blaCTX-M-
15  
9 (8.5%) 617 (n=2), 744 (n=2), 4981 (n=2), 167 
(n=1), 410 (n=1), 58 (n=1) 





5 (4.7%)  457 (n=2), 101 (n=1), 165 (n=1), 744 
(n=1) 
MN, MO, KS 
blaCTX-M-
14 
2 (1.9%)  10 (n=2) IL 
blaSHV-
12* 
2 (1.9%)  10 (n=2), 641 (n=2), 1112 (n=1)* MN, NE, IL, OK 
blaCTX-M-
27 
3 (2.8%)  10 (n=1), 744 (n=1), 1585 (n=1) MN, NE, OK 
*- 3 of these isolates had ceftiofur MIC value <8 g/ml 
 
Table 5-2. Pattern of genetic determinants of fluoroquinolone resistance in E. coli clinical 




Pattern of genetic determinants 
(n=number of isolates) 
ST types (n=number of isolates) 
>2  gyrA(S83L) + gyrA(D87Y or D87N 
or D87G) + parC(S80I or S80R)  
parC(A56T or E84G)  parE(S458A 
or L416F)  single PMQR (aac(6’)-
Ib-cr, qnrB77, qnrB15 or qnrB19) 
(n=49) 
744 (n=11), 100 (n=10), 224 (n=4), 
410 (n=3), 10 (n=2), 457 (n=2), 
617 (n=2), 4981 (n=2), 88 (n=1), 
93 (n=1), 167 (n=1), 977 (n=1), 




2 gyrA(S83L) + parC(S80I or S80R) 
(n=23) 
100 (n=21), 58 (n=1), 90 (n=1) 
qnrB19 (n=2)  361 (n=1), 2496 (n=1) 
No genetic determinants (n=1) 5926 (n=1) 
1 gyrA(S83L) + parC(S80I or S80R) 
(n=7) 
100 (n=6), 69 (n=1) 
gyrA(S83L) only (n=1) 6234 (n=1) 
gyrA(D87G) + qnrB2 (n=1) 10 (n=1) 
qnrB19 + qnrS2 (n=1) 101 (n=1) 
aac(6’)-Ib-cr + qnrB2 (n=1) 540 (n=1) 
Single PMQR (qnrB19, qnrS1, 
qnrS2, qnrB2 or qnrB15) (n=6) 
10 (n=3), 641 (n=1), 847 (n=1), 
5759 (n=1) 


















ST types Collection 
location 
Number of isolates 
with enrofloxacin 
MIC (<1 µg/ml) 
(n=119) carrying 
PMQR genes 
Number of isolates 
with enrofloxacin 
MIC (=>1 µg/ml) 
(n=93) carrying 
PMQR genes 





















qnrS1 (n=2) 10, 641 MN, KS 0 2 
qnrS2 (n=4) 10, 101, 
847 













Table 5-4. Characteristics of plasmids assembled in this study 
Isolate 
no. 







Other AMR genes Mobile genetic elements 
flanking bla and qnr genes 
p1CTX blaCTX-M-15 170 kbp IncF 
(F31:A4:B1) 
617 aadA5, aac(3)-IIa, aac(6’)-Ib-
cr, blaOXA-1, mph(A), catB3, 
sul1, tet(B), dfrA17  
ΔISEcp1- blaCTX-M-15-Tn3 
p2CTX blaCTX-M-15 170 kbp IncF 
(F31:A4:B1) 
58 aac(6’)-Ib-cr, blaOXA-1, 
mph(A), tet(B), dfrA17 
ΔISEcp1- blaCTX-M-15-Tn3 
p4CTX blaCTX-M-15 115 kbp IncF 
(F48:A1:B49) 
744 aac(3)-IIa, blaTEM-1b, mph(A), 
dfrA17 
ISEcp1- blaCTX-M-15-IS26 
23 blaCTX-M-15 Chromosomal 
 
4981 mdf(A) ΔISEcp1- blaCTX-M-15-Tn3 
p23qnr qnrB15 60 kbp IncN 
(unknown) 
4981 aac(3)-Iid, aadA2, aph(3’)-Ia, 
aph(6)-Id, aph(3’’)-Ib, blaTEM-




p33SHV blaSHV-12 300 kbp IncHI2 (ST-1) 641 aac(6’)-Ib3, aac(6’)-Iic, 
aph(6’)-Id, aph(3’’)-Ib, aadA2, 
blaTEM-1b, aac(6’)-Ib-cr, qnrB2, 
ere(A), sul1, sul2, dfrA19 
IS26- blaSHV-12-IS26 
p37CTX blaCTX-M-27 69 kbp IncF (F21*:A-
:B-) 
744 erm(B) ΔISEcp1- blaCTX-M-14-IS5 
p39SHV blaSHV-12 300 kbp IncHI2 (ST-1) 1112 aph(3’’)-Ib, a[h(6)-Id, aph(3’)-
Ia, aac(6’)-IIc, blaTEM-1b, mcr-
9, ere(A), catA2, sul1, tet(D) 
IS26- blaSHV-12-IS26 
p65CTX blaCTX-M-55 240 kbp IncHI2 (ST-2) 165 aac(3)-IIa, blaTEM-1b, mph(A), 
dfrA17 
ΔISEcp1- blaCTX-M-55-ΔIS6 
p62CTX blaCTX-M-27 69 kbp IncF (F21*:A-
:B-) 
10 - IS5- blaCTX-M-27-ΔISEcp1 
p77CTX blaCTX-M-14 77 kbp  IncF 
(F2:A8:B56) 






















































77 kbp IncF 
(F2:A8:B56) 
1 74 >99% 
blaCTX-
M-15 
p1-CTX-M 171 kbp IncF 
(F31:A4:B1) 
3 132 (101-161) >99% 
blaCTX-
M-15 
p4-CTX-M 113 kbp IncF 
(F48:A1:B49
) 





75 kbp IncF 
(F21*:A-:B-) 





240 kbp IncHI2 (ST-
2) 
1 201 >99% 
blaSHV-12 p33-SHV 301 kbp IncHI2 (ST-
1) 
3 289 (281-293) >99% 
qnrB15 p23-qnr 59 kbp IncN 2 57 (57-57) >99% 
qnrB19 MK191839.
1  





59 kbp IncN 2 43 (42-43) >99% 




Table 5-6. Characteristics of isolates carrying mcr-9 genes 
Isolate ST 
type 
Other AMR genes in the isolate 

















Figure 5-1. Maximum likelihood tree representing the phylogenetic relationships between 








CHAPTER-6 General Discussion 
 
This dissertation provides new data that can improve our understanding on the global 
situation of resistance to critical antimicrobials in indicator bacteria from swine, on the 
prevalence of AMR in E. coli and other bacterial pathogens (S. suis, P. multocida, A. suis 
and H. parasuis) isolated from diseased pigs in USA, and on the genomic determinants 
conferring extended spectrum cephalosporin and fluoroquinolone resistance in selected 
swine clinical E. coli isolates collected in USA. In chapter 2, we conducted a systematic 
review and meta-analysis to estimate the global prevalence of cephalosporin, quinolone, 
colistin and carbapenem resistance in E. coli from different swine sources. Although it is 
widely reported that human isolates collected in LMIC are more resistant to different 
antimicrobials compared to isolates from UIC, such comparisons between AMR in UIC 
and LMIC isolates from food animals have not been performed on a global scale. In our 
study we also observed higher prevalences of AMR in swine E. coli isolates from LMIC 
compared to UIC across different sources (healthy pigs, diseased pigs, porcine meat 
products). It was encouraging to see that the prevalence of carbapenem resistance was 
globally very low in swine E. coli isolates with a few exceptions. Carbapenems are the 
last class of antimicrobials introduced in human medicine and are effective against a 
broad spectrum of bacteria. Ideally these low levels should be maintained and constantly 
monitored in swine E. coli isolates due to their importance from a public health point of 
view. Another interesting finding was that data availability and consistency was higher in 
UIC compared to LMIC. For some of the bacteria-antimicrobial combinations in LMIC, 
data available was coming from only a few studies or even a single study, leading to huge 
uncertainty in the estimates. Simply put, we have an indication of moderate to high 
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prevalence of resistance to critical antimicrobials but the lack of reliable information 
hinders much of the prevalence and trend analyses conducted. It would be advisable for 
countries such as India, China and Vietnam to include swine populations in their AMR 
surveillance activities as they set up their programs. Similarly, the number of studies 
focusing on prevalence of genetic determinants conferring resistance, as well as the 
number of isolates in these studies, were lower for articles from LMIC compared to UIC 
except for China. Hence, genotypic prevalence of AMR in isolates from LMIC remains 
understudied and future studies should incorporate components of genomic surveillance, 
particularly in LMIC.  
 In chapter 3, changes in prevalence of single and multiple AMR phenotypes in 
swine clinical E. coli isolates in USA were studied. The patterns of infdvidual AMR 
remained realtively stable or changed modestly for all of the antimicrobials evaluated 
except enrofloxacin, for which the prevalence of AMR increased drastically from 2008 
onwards. Enrofloxacin has only been recently introduced for treatment of swine enteric 
and respiratory diseases in USA, and based on our findings the prevalence of 
enrofloxacin resistance in isolates coming from various sources (healthy pigs, diseased 
pigs, pork) should be continuously monitored, and use of enrofloxacin be regulated as 
needed. Changes in multiple AMR was estimated by classifying an isolate as being 
multiple antimicrobial resistant if they are resistant to 3 or more than antimicrobial 
classes and running logistic regression model. This model revealed a slight decrease in 
the proportion of isolates carrying multiple AMR over the study-period. However, 
resistotype analysis using rarefaction curves and networks of AMRs revealed an increase 
in the number of AMR combinations and increased strengths and density of AMR 
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networks over the years. This increase in AMR complicates the threat posed by resistant 
bacteria as use of antimicrobials can co-select for different classes of antimicrobials. 
These AMR networks should be treated as hypothesis generating tools, and field trials 
can further elucidate how the use of different antimicrobials can co-select for other 
antimicrobial classes. For example, associations between ceftiofur usage on resistance to 
other antimicrobials (e.g. florfenicol) can be estimated in actual field conditions to check 
whether the correlation between ceftiofur-florfenicol resistance observed in this chapter 
holds true in field conditions. Changes in AMR should be surveyed continously using 
diagnostic data starting January 2017 and compared with the results presented here. This 
comparison will likely provide an indication of success or failure of veterinary feed 
directive in reducing prevalence of AMR. Additionally, antimicrobial usage data should 
be incorporated in these univariate nad multivariate models to elucidate the extent of 
antimicrobial usage on evolution of AMR. 
 In chapter 4, we assessed the presence of changes in the prevalence of AMR in 
certain swine bacterial pathogens (S. suis, P. multocida, A. suis and H. parasuis) isolated 
in USA. The prevalence of AMR for those bacteria-antimicrobial combination for which 
clinical breakpoints were available remained consistently low (< 12%) with the only 
exception of tetracyclines. This suggest that certain antimicrobials have remained 
clinically effective against S. suis and P. multocida. However, for bacteria-antimicrobial 
combinations with no breakpoints available, ordinal regression models estimated 
significant increases or decreases in the odds of having higher MIC values. Lack of 
availability of clinical breakpoints or epidemiological cut-offs significantly hampered the 
interpretation of results coming fromthese regression models though, as we were not able 
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to make strong clinical or epidemiological inference based on them and secondly, the 
results were contradictory for several bacteria-antimicrobial combinations despite using 
the least parsimonious ordinal regression models with odds decreasing at certain MIC 
level but increasing for some other MIC levels for same antimicrobial-bacteria 
combination. Statistical models (multivariate network of AMR in chapter 3, ordinal 
regression models in chapter 4) based on the analysis of MIC values without applying 
breakpoints can provide an indication of an increase or decrease in AMR above/below 
these, but the clinical decision making and interpretation and reporting of results to 
stakeholders can become more difficult. A combined statistical approach where 
breakpoints can be used to make binary logistic regression models (as done in chapters 1 
and 2) and ordinal regression models based on MIC distributions (chapter 4) that can 
detect minor shifts in MIC values can serve as a complete and interpretable alternative for 
the analysis of AMR. Authors have also used breakpoints from related bacteria as a proxy 
to study the prevalence of AMR. Our study suggests that this is a rather limited approach 
to circumvent the absence of breakpoints and should be avoided. Future studies should 
focus instead on establishing both phenotypic and/or genotypic breakpoints for bacteria 
critical for swine health such as H. parasuis and A. suis.  
 In chapter 5, the presence of genetic determinants of extended-spectrum 
cephalosporins and fluoroquinolone resistance was assessed in selected swine E. coli 
isolates presenting different resistance phenotypes. We found a higher proportion of 
ceftiofur resistant E. coli carrying ESBL encoding genes compared to previous studies. 
These ESBL encoding genes have become the dominant mechanism behind resistance to 
3rd or higher generation cephalosporins and their prevalence should be continuously 
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monitored to establish whether these genes become dominant in swine bacterial 
populations in the near future as has happened in other parts of the world. Indeed, 
plasmids carrying these genes were similar to plasmids that have been involved in the 
global expansion of ESBL encoding genes, and these plasmids have been successful in 
the dissemination of extended spectrum cephalosporin resistance both in-vitro and in-
vivo. Plasmid mediated resistance genes and chromosomal mutations alone or in 
combinations were responsible for conferring various degrees of enrofloxacin resistance 
in the assessed isolate collection. PMQR genes and plasmids similar to those previously 
reported in isolates from retail pork and healthy pigs were found in our collection, which 
gives strength to the hypothesis that studying AMR in clinical isolates can be indicative 
of emerging resistance determinants in healthy animal populations and in turn, in the food 
chain. The complete plasmid assemblies generated in this study can be used for 
genomics-based source attribution models in the future. Future studies should include 
measuring the fitness of isolates carrying ESBL encoding genes and their potential for 
dissemination in in-vitro and in-vivo conditions. The plasmids and E. coli genomes 
drafted in this study can also be compared with those drafted from humans or other food 
animals retrospectively and prospectively to strengthen source-attribution models that are 
based on genetic data. 
 In conclusion, these studies provide an insight into the changes in phenotypic and 
genotypic prevalence of AMR in different bacteria of animal and human health 
importance collected from clinically affected swine populations in USA. Additionally, 
this thesis also includes a comprehensive systematic review of the global prevalence of 
resistance to critical antimicrobials in isolates recovered from different swine sources, 
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which helps putting the results on AMR distribution in USA isolates in a global context 
and also highlights the need to include and improve surveillance of AMR in swine 
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